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CHAPTER I 
 
INTRODUCTION 
 
Staphylococcus aureus and Bacillus anthracis are important human pathogens. 
 Staphylococcus aureus is a Gram positive commensal organism that inhabits the anterior 
nares of 30% of the population (27). While colonization of the nares is relatively harmless, once 
S. aureus crosses the host epithelium it is capable of infecting nearly any host tissue. The 
morbidity and mortality associated with S. aureus infections are high and treatment is often 
challenging as S. aureus is constantly developing resistance to antibiotics. The ubiquitous 
presence of S. aureus in the human population, its ability to infect nearly any human tissue, and 
the increasing incidence of hospital-acquired and community-acquired multi-drug resistant S. 
aureus (MRSA) infections are reasons for alarm and highlight the necessity for identifying novel 
therapeutic targets to combat this pathogen. 
 Bacillus anthracis and S. aureus both belong to the Bacillales order of the Firmicutes. 
Among many differences from S. aureus, B. anthracis forms spores and primarily causes disease 
in livestock. Infection of humans with B. anthracis spores by either ingestion or inhalation is 
often associated with septicemia. Once the spores enter the blood, they germinate to vegetative 
cells which divide rapidly and at the time of death may account for 30% of a human’s blood 
weight (21). The resiliency of and the mortality associated with B. anthracis spores makes the 
bacterium a potential bioweapon, as evidenced by the 2001 attacks sent through the US postal 
service. As such, a great deal of biodefense research has focused on anthrax pathogenesis, which 
is important for developing vaccines and treatments to protect humans from this biological threat. 
 B. anthracis and S. aureus are both pathogens that pose a significant threat to public 
health. Infections by either of these bacteria consist of a significant blood-component suggesting 
that they have intimate interactions with host leukocytes and erythrocytes. Defining how these 
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pathogens adapt to the host environment, particularly the blood, is imperative for advancing the 
methods by which we treat these aggressive infections. 
 
Iron is an essential nutrient for pathogens. 
 Iron is a transition element with a high redox potential. This makes it a valuable cofactor 
for enzymes involved in protecting bacteria from host defenses, DNA replication, and respiration. 
Since iron is intimately involved in basic physiological processes, almost all pathogens require 
iron to successfully infect their hosts (96). At physiological pH, however, ferric iron is highly 
insoluble. Coordinating iron within a tetrapyrrole ring as ferriprotoporphyrin IX (heme) 
solubilizes iron and enhances its catalytic ability by 5 to 10 orders of magnitude (9). This 
catalytic activity is harnessed by hemoproteins involved in oxygenation reactions, oxidative stress 
responses, electron transport, oxygen transport, oxygen sensing, and oxygen storage. Both S. 
aureus and B. anthracis have the machinery to synthesize endogenous heme from glutamyl-
tRNAGlu (57). While endogenous heme biosynthesis allows pathogens to solubilize, store, and 
augment the utility of iron, exogenous iron is still required for heme biosynthesis. In the 
vertebrate host, a major source of iron is in the form of heme bound to host hemoglobin in 
erythrocytes in the blood, a site accessed by both S. aureus and B. anthracis. Little is known 
about the dynamics between endogenously synthesized and exogenously acquired heme during 
bacterial pathogenesis. Data presented in Chapter II increase our understanding of the 
mechanisms by which S. aureus regulates endogenous heme biosynthesis.  
 
Heme is both an iron source and a toxic liability to bacteria. 
 Since heme is the most abundant iron source in the vertebrate host and a valuable 
nutrient, bacterial pathogens have many systems for acquiring host heme. Both S. aureus and B. 
anthracis utilize the iron-regulated surface determinant (Isd) system to acquire heme-iron during 
infection (67). Once heme enters the cytoplasm it is degraded by IsdG family heme oxygenases to 
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staphylobilin and free iron (68). In iron-replete conditions, however, heme is no longer degraded. 
Instead, it is trafficked to the cell membrane where it is most likely used as a cofactor in proteins 
involved in respiration (77). S. aureus and B. anthracis both dedicate significant efforts to 
acquiring heme however too much heme is toxic to the bacteria (48, 83). While much is known 
about the mechanisms of heme toxicity in eukaryotes, most are not applicable to bacteria (1). The 
mechanisms by which heme is toxic to bacteria seem to be distinct from those in humans, yet they 
remain ill-defined (1). Currently there exist two ideas for the mechanism of bacterial heme 
toxicity. One suggests that DNA damage by heme is a source of toxicity to the cell, while the 
other proposes that heme-menaquinone interactions generate a superoxide generating cycle that is 
detrimental to S. aureus (44, 93). While identifying the source of heme toxicity is of great 
interest, studies presented here focus primarily on the mechanisms by which S. aureus and B. 
anthracis sense and alleviate heme toxicity. 
 
S. aureus and B. anthracis sense heme to alleviate its toxicity. 
 Previous work revealed that pre-treating either S. aureus or B. anthracis with a sub-toxic 
concentration of heme protects both bacteria from heme toxicity (90). This protection is mediated 
by the two-component signaling (TCS) system, heme sensor system (HssRS) (Figure 1). In the 
presence of heme the HssS histidine kinase (HK) is auto-phosphorylated at a conserved histidine 
residue (Figure 1A) (83, 85). HssS then transfers this phosphate to an aspartic acid on its cognate 
response regulator (RR) HssR (Figure 1B). This activates HssR and allows it to bind to a 
conserved direct repeat (DR) in the promoter region upstream of the heme regulated transporter 
(hrtAB) to initiate transcription (Figures 1C-D). HrtAB is an ABC transporter that alleviates heme 
toxicity by a yet-to-be determined mechanism, most likely heme efflux (Figure 1E) (42). While 
the signaling pathway responsible for protecting S. aureus and B. anthracis from heme toxicity 
has been well-characterized, the ligand of HssS remains elusive. This is not uncommon for a 
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TCS, as less than 20 ligand-sensor pairs have been assigned for the over 20,000 predicted TCSs 
(40).  
 
Heme sensing is conserved across Gram positive pathogens. 
 Heme sensing systems are found in many bacteria and the hss/hrt system is evolutionarily 
conserved across many Gram positive bacteria. This includes several pathogens such as 
Staphylococcus epidermidis, Bacillus cereus, Listeria monocytogenes, Listeria inocua, and 
Enterococcus faecalis (12, 84). The hss/hrt systems are generally found in either pathogenic or 
saprophytic Gram positive bacteria. For example, hss/hrt systems are found in B. anthracis, B. 
cereus, and B. thuringiensis, but not B. subtilis and B. licheniformis (83). In fact, B. subtilis and 
B. licheniformis are both more sensitive to heme toxicity than any of the Bacilli that encode an 
hss/hrt system. These observations suggest that the hss/hrt system is maintained by bacteria that 
come in contact with host blood and that it might be used to signal to the bacteria that they have 
entered their host. 
 Aside from the initial identification and characterization of HssRS and HrtAB in S. 
aureus and B. anthracis, orthologous HrtAB systems have been most thoroughly described in 
Lactococcus lactis and Streptococcus agalactiae (18, 42, 61, 82, 83, 85, 90). Neither of these 
species synthesize their own heme and as such require exogenous heme to activate respiration 
(17, 98). Although the function of HrtAB in each of these species is analogous to HrtAB in S. 
aureus and B. anthracis, each species has its unique strategy for maintaining heme homeostasis. 
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Figure 1. The HssRS two-component signaling system. A. In the presence of heme the HssS 
histidine kinase autophosphorylates at a conserved histidine residue located on the intracellular 
domain. B. The phosphate is transferred from HssS to a conserved aspartic acid on its cognate 
response regulator HssR. C. HssR is activated and binds to a conserved direct repeat DNA 
sequence in the promoter region of hrtAB. D. This increases expression of the heme-regulated 
transporter HrtAB. E. HrtAB alleviates heme toxicity by a yet-to-be-determined mechanism. 
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 S. agalactiae encodes orthologous HssRS and HrtAB systems (18). S. agalactiae HssRS 
is stimulated by heme and results in high expression of hrtAB in the concentration range of 1 to 
10 μM heme (18). Distinct from S. aureus and B. anthracis, S. agalactiae also encodes two other 
dual heme and protoporphyrin IX (PPIX) efflux pumps, pefAB and pefCD (18). These two efflux 
pumps are repressed by the MarR-superfamily repressor, PefR, at concentrations of less than 0.3 
μM heme and 1 μM PPIX (18). The observation that pefAB and pefCD are activated at low heme 
and PPIX concentrations, while hrtAB is activated at higher heme concentrations suggests that the 
pef transporters are utilized to fine tune intracellular heme and PPIX levels while hrtAB is 
employed to protect S. agalactiae from heme toxicity in heme-rich environments (18). The 
differential activity of two heme-regulated transport systems highlights the delicate lifestyle S. 
agalactiae strives to maintain in order to cope with the heme paradox (1). 
 L. lactis also encodes an orthologous hrtBA (ygfBA) that, when mutated, results in 
increased sensitivity to heme toxicity (61). However, a corresponding HssRS TCS has not been 
identified in this species. Instead, L. lactis encodes a unique TetR-family transcriptional regulator, 
hrtR (ygfC), adjacent to hrtBA (42). HrtR binds heme, which alleviates HrtR repression of the 
hrtRBA operon promoter and increases expression of HrtR and HrtAB at heme concentrations 
ranging from 1 to 5 μM (42). Notably HrtR is also responsive to GaPPIX, but not most other 
metalloporphyrins (42). In L. lactis ∆hrtRBA, over-expression of hrtBA results in reduced 
accumulation of heme, suggesting that HrtAB is a heme efflux pump in L. lactis (42). Currently, 
these results have not been confirmed in any other hrtAB encoding bacterial species. 
 These studies of heme homeostasis in other Gram positive bacteria highlight the unique 
strategies bacteria employ in order to balance the energetic benefits of heme with its toxicity. This 
underscores the importance of maintaining appropriate intracellular levels of heme in diverse 
environments.  
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The ability to resist heme toxicity is important in pathogenesis. 
 TCSs are the primary way that bacteria adapt to environmental changes. Since heme is a 
host molecule it is likely that HssRS is activated during infection. This hypothesis is supported by 
the observation that the hrt promoter is transcriptionally active during B. anthracis infection (83). 
Furthermore the importance of HssRS heme sensing during bacterial pathogenesis is highlighted 
by the observation that BALB/c mice infected with S. aureus ∆hssR have significantly increased 
bacterial burdens in the livers (90). Taken together, these results support that HssRS mediated 
protection against heme toxicity during infection maintains the bacteria in a less virulent state. As 
such, small molecule activators of HssRS may be viable therapeutics for treating patients with 
aggressive S. aureus or B. anthracis infections. 
 
A chemical genetics approach for studying bacterial signal transduction. 
 TCS signaling in response to host stresses is a critical aspect of bacterial adaptation to the 
host and other environmental changes. Years of probing TCS activity and function using classical 
genetic and biochemical techniques have provided insights into their biology. The scientific 
community has now identified a small fraction of the ligand-sensor pairs and come to understand 
some mechanisms by which TCS signaling purity is maintained; yet there are hints that bacterial 
signaling transduction may be more complex than previously thought. In order to further the 
field’s understanding of bacterial signaling networks, new strategies need to be employed. A 
chemical genetics approach has been applied to HssRS and TCS biology here. 
 Chemical genetics is similar to classical genetics, but instead of using molecular 
techniques to study gene function, small molecules are used instead. To illustrate this more 
clearly, consider the example of identifying the genes required for protein secretion in S. aureus. 
In forward genetics, a genome would be randomly mutagenized to create a library of mutants and 
then that library would be screened for loss of protein secretion. Identifying the mutagenized gene 
that results in that loss of protein secretion ascribes a role of that gene in the production of protein 
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secretion. However, what if the genes required for protein secretion are essential? Or, what if 
multiple genes need to be disrupted to affect protein secretion? When combined with chemical 
genetics, some of these limitations may be overcome. Continuing with the example from above, 
the chemical genetics approach would screen a library of small molecules for effecting loss of 
protein secretion in bacteria. By characterizing the activity of the small molecules at a cellular 
level, other aspects of protein secretion may be elucidated.  
 A chemical genetics approach was undertaken to expand the current understanding of 
heme homeostasis and signaling networks in S. aureus and B. anthracis and to complement 
previous studies probing bacterial heme sensing by more classical approaches. The work 
described here has developed two small molecule activators of HssRS into tools for studying 
bacterial physiology and signal transduction and defines their potential use in perturbing bacterial 
pathogenesis. 
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CHAPTER II 
 
MECHANISM OF HssRS ACTIVATION BY SMALL MOLECULE VU0038882 
 
Introduction 
 Staphylococcus aureus is a commensal organism that primarily colonizes the anterior 
nares, as well as the skin (30). Upon breaching the epithelium of its host, S. aureus has the 
potential to infect virtually any tissue. This adaptability reflects the capacity of S. aureus to sense 
a variety of environmental signals and integrate them into its metabolic program enabling growth 
in diverse host niches. 
 Upon entering the iron-poor environment of the vertebrate host, the cellular program to 
import ferriprotoporphyrin IX (heme) from host hemoglobin into the cell is activated in order to 
satisfy cellular iron and heme requirements (51). S. aureus may also synthesize heme 
endogenously through the coordinated effort of enzymes encoded by the hemAXCDBL, hemEHY, 
and hemN operons, although this process requires that iron and other building blocks be available 
to the bacteria (33). The ability to exogenously acquire and endogenously synthesize heme allows 
S. aureus to satisfy cellular iron and heme requirements in diverse environments. This strategy is 
typical for most bacterial pathogens and reflects the integral role of heme in metabolism and 
physiology; however, the distinct contributions of endogenous and exogenous heme to the 
cellular physiology of bacteria are unknown. 
 Heme is a co-factor required for respiration. Furthermore, S. aureus respiration requires 
that the bacteria either synthesize or assimilate the electron carrier menaquinone (MK) and that a 
terminal electron acceptor be available. During respiration, reducing equivalents derived from the 
oxidation of carbon sources are donated to MK. The shuttling of electrons by MK through the 
electron transport chain generates a proton motive force (pmf) across the cytoplasmic membrane. 
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The energy stored in the pmf powers ATP synthesis and nutrient import. When heme, MK, or 
terminal electron acceptors are absent, S. aureus captures energy through fermentation. 
Fermentation employs substrate-level phosphorylation, which produces acid end products, to 
generate ATP and maintain the redox balance of the cell. Figure 2 outlines central metabolism in 
S. aureus. 
 Without heme, central metabolic pathways and enzymes cannot function; however, 
excess heme is toxic due to its redox cycling properties (93). Prior exposure of S. aureus to 
subinhibitory concentrations of heme increases heme tolerance (90). This adaptation is due to the 
heme-induced increase in expression of HrtAB, an efflux pump that protects the bacteria from 
heme toxicity. The increased expression of hrtAB is mediated by the heme sensor system (Hss) 
two-component system (TCS). While the signaling pathway of HssRS has been previously 
described, the mechanism of activation remains to be determined. Defining the mechanisms by 
which HssRS is activated would reveal the signals that alert S. aureus to adapt to its host and 
inform the rational design of new therapeutic strategies that could subvert S. aureus energy 
homeostasis during infection. 
 In this study, the mechanism of HssS stimulation was probed by identifying small 
molecule activators of HssS. The most potent compound, VU0038882 (‘882), activates HssRS by 
inducing endogenous heme biosynthesis in S. aureus and leads to increased intracellular heme 
levels. A transposon screen for ‘882-insensitive mutants revealed that perturbations in central 
metabolism influence heme homeostasis. These studies have provided new insights into heme 
homeostasis and HssRS activation in S. aureus and highlight the utility of ‘882 as a powerful 
probe of bacterial physiology.  
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Figure 2. A schematic of central metabolism in S. aureus. Carbon sources such as glucose are 
brought into the cell and converted to pyruvate. During fermentation pyruvate is metabolized to 
acid end products such as lactate, ethanol, and acetate. The conversion of pyruvate to acid end 
products produces ATP and maintains the redox balance of the cell by regenerating NAD+. 
During respiration, pyruvate is shuttled into the TCA cycle. The conversion of pyruvate in the 
TCA cycle produces some ATP and many reducing equivalents in the form of NADH. The 
electrons from NADH are abstracted and shuttled through the electron transport chain by the 
electron carrier menaquinone. This transfer of electrons extrudes protons and generates a proton 
motive force (pmf). The pmf is harnessed by ATP synthase to produce more ATP for the cell. 
The cytochromes involved in electron transport require heme and menaquinone in order to 
successful shuttle electrons. Without heme or menaquinone, respiration does not occur. 
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Methods 
Bacterial strains and growth conditions - Staphylococcus aureus strains Newman, ∆hssR, ∆hssS, 
∆hssRS, ∆menB and ∆isdG have been described previously (16, 51, 83, 90, 93). S. aureus 
hemB::ermC (∆hemB) has been described previously and was transduced into Newman using 
bacteriophage Φ-85 (51, 92). The ∆pfkA deletion construct (pBT2-∆pfkA) was made by cloning 
the flanking regions of the S. aureus pfkA gene (primers: pfkA-5.1A, pfkA-5.1B, pfkA-3.1A, 
pfkA-3.1B) into the S. aureus/E. coli shuttle vector pBT2ts (53). This construct was then used to 
make an in-frame deletion of the pfkA gene in the wildtype S. aureus Newman background as 
previously described using TSB media without dextrose supplemented with 1% sodium pyruvate 
(23). Corynebacterium diphtheriae strain HCL2 and Staphylococcus haemolyticus strain NRS9 
were used. 
 All S. aureus strains were grown on tryptic soy agar (TSA) containing 10 µg/ml 
chloramphenicol when appropriate and grown at 37°C for 20-30 h. All overnights were grown in 
5 ml of tryptic soy broth (TSB) at 37°C with shaking at 180 rpm unless otherwise noted. Unless 
stated otherwise, vehicle treatment refers to a volume of DMSO comparable to the volume added 
containing the described compound (‘882). 
Small molecule library screen with luciferase reporter - An overnight of Newman phrt.lux was 
sub-cultured into 500 ml in a 1.5 L flask. The cells were grown for 1.5 h to an OD600 between 
0.60–0.65. Seventy-five μl of culture were transferred into each well of a 384 well, flat-bottom 
plate containing synthetic compounds that resulted in a final concentration of 6.7 μM. DMSO and 
heme were used as negative and positive controls, respectively. The plates were incubated for 3 h. 
Luminescence values were measured either using a Synergy HT Multi-Mode Microplate Reader 
(Biotek, Inc.) or TopCount NXT™ Microplate Scintillation and Luminescence Counter 
(PerkinElmer, Inc.). A compound was considered a hit if the raw luminescence value exceeded 
the luminescence of cells grown in the presence of 81.25 nM heme. 
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XylE reporter assays - XylE assays were performed as described previously with modifications in 
growth conditions (90). For the ΔhemB experiments, overnights were sub-cultured 1:50 into 0.5 
ml of media for 4 h. For all other reporter assays, the bacteria were grown for 9 h and diluted 
1:100 into 0.5 ml of media for 15 h. 
Chemical libraries - The synthetic compounds were obtained from the Vanderbilt Institute of 
Chemical Biology (VICB) collection, which is a high-diversity, synthetic small-molecule library 
consisting of approximately 160,000 compounds. Select compounds were repurchased from 
either ChemBridge or ChemDiv. 
Growth curve analyses - Overnight cultures of Newman were diluted 1:100 into 100 μl of media. 
Bacterial cells were incubated and the OD600 was measured at the specified time points. For all 
staphylococcal adaptations, cultures were inoculated in 0.5 ml of TSB for 1 h at 37°C, 180 rpm 
and sub-cultured 1:100 in 100 ul of media containing the indicated additive. Cultures were pre-
adapted overnight and analyzed as described above for a typical growth curve. 
 C. diphtheriae was inoculated into TSB containing vehicle, 5 µM heme, or 50 µM ‘882 
and grown for 22-24 h. Cultures were diluted 1:50 into 5 ml of media containing 15 µM heme 
and grown with shaking at 180 rpm and 37°C. CFUs were enumerated on TSA. 
Transposon library generation and screen - A transposon library was generated using Tn917 (8). 
The pTV1 transposition vector was transformed into S. aureus Newman and selected for on TSA 
containing erythromycin (10 μg/ml) and chloramphenicol (10 μg/ml). Tn917 transposition was 
induced on TSA-erythromycin (10 μg/ml) at 43°C for 24 h and mutants were screened for 
chloramphenicol sensitivity and erythromycin resistance in TSB at 37°C. Transposon mutants 
were arrayed in 96 well plates and stored at -80°C. 
 Mutants were revived in 150 μl of TSB and grown for 7 h before being sub-cultured 1 μl 
into 100 μl of 40 μM ‘882 in TSB and incubated overnight. Cultures were diluted 1:100 into 100 
μl of TSB containing 20 μM heme. Bacterial cells were incubated and the OD600 was measured at 
5 h and 7 h. Mutants with an OD600 more than 2 standard deviations below the plate average were 
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isolated for single colonies on TSA-erythromycin (10 μg/ml) and confirmed in a second 
adaptation in triplicate. 
Transposon integration site identification - Transposon mutants were isolated on TSA-
erythromycin (10 µg/ml) and grown overnight in TSB-erythromycin (10 µg/ml). Genomic DNA 
was isolated from 4 ml of the overnight using a Wizard Genomic purification kit (Promega). 
Genomic DNA (2 µg) was digested with DraI at 37°C overnight. DraI was heat inactivated and 
200 µg of the digested DNA ligated at room temperature for 2 h. Ligated DNA (20 ng) was PCR 
amplified using DLS479 and DLS480 (53). PCR products were treated with exonuclease I (NEB) 
and SAP (Promega) according to the manufacturer’s instructions. PCR-amplified DNA was 
column purified using a PCR Purification Kit (Qiagen) and sequenced using DLS493 or DLS494 
(53). The sequence flanking the tn917 inverted repeat was used to interrogate the S. aureus 
Newman genome sequence to determine the tn917 integration site. Some integration sites were 
identified using previously published methods (2). 
Metabolite detection - An overnight of Newman was diluted 1:100 in 125 ml of TSB containing 
either vehicle or 40 µM ‘882. Each hour, 5 ml of culture were sampled and pelleted by 
centrifugation at 3,200 x g. The pH of the supernatant was measured using a SevenEasy pH meter 
(Mettler Toledo). Glucose and lactate concentrations were quantified according to the manual (r-
Biopharm) with the assays scaled to a final volume of 300 µl. 
 For the characterization of ΔpfkA, cultures were grown overnight at 37°C, in TSB+P (1% 
sodium pyruvate), with shaking at 250 rpm. Cultures were diluted to an OD660 of 0.05 in 8 ml of 
TSB+P and incubated at 37°C with shaking at 250 rpm (18x150 mm culture tube). Each hour, 
350 µl of culture were sampled and analyzed for absorbance (OD660). Two-hundred µl were 
pelleted at 16,000 x g for 1 min and the supernatants frozen at -20°C. Samples were thawed on 
ice. The pH was measured using Sigma pH Tests Strips (P-3536) and glucose levels were 
quantified using the R-Biopharm D-Glucose Kit (10 716 251 035). 
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Pyridine hemochromogen heme quantification assay - Bacteria were grown for 8 h. The cultures 
were diluted 1:100 and grown aerobically for 15-17 h. Pellets were washed in 0.5 ml of 20 mM 
K2HPO4/KH2PO4 (pH 7.6) and resuspended in 0.5 ml of 20 mM K2HPO4/KH2PO4 (pH 7.6) 
containing 30 µg of lysostaphin and incubated at 37°C for 20 min. Each sample was lysed by 
sonication and the protein concentration determined using a Pierce BCA Protein Assay Kit 
according to the manual (Thermo Scientific). Heme was extracted by adding an equal volume of 
0.4 M NaOH and 40% pyridine and quantified as previously described using an extinction 
coefficient of 324 mM-1cm-1 (71). 
Heme quantification by LC-MS - S. aureus was grown in 5 ml of TSB for 8 h and sub-cultured 
1:250 into 300 ml of TSB containing DMSO or 40 μM ‘882. Cells were grown at 37°C, 200 rpm 
for 15 h and CFUs were enumerated. Cells were pelleted at 10,500 x g for 15 min and the pellets 
were washed in 30 ml of 20 mM potassium phosphate (pH 7.6). Cells were pelleted at 3,200 x g 
for 20 min and the pellets were resuspended in 40 ml of TSM (100 mM Tris-HCl pH 7, 500 mM 
sucrose, 10 mM MgCl2) containing 25 μg/ml lysostaphin. Cells walls were digested at 37°C for 
20 min and the samples were pelleted at 10,500xg for 15 min. The protoplast pellets were flash 
frozen in liquid N2, and maintained at -80°C. Protoplast pellets were weighed and thawed in 7 ml 
of 0.1 M potassium phosphate buffer, pH 7.  WT and ‘882-treated protoplast samples were 
sonicated (3 s on, 2 s rest, 50% amplitude, Branson 4c-15) on ice: four 5 min rounds, 5 min rest. 
The samples were then centrifuged for 50 min at 6,400 x g. The cleared lysates were syringe 
filtered (0.45 m, Millipore) and diluted as needed to allow the measured extracted ion 
chromatogram (EIC) peak area to fit on the standard curve. 
Porphyrin standards were purchased from Frontier Scientific Inc. (Logan, UT).  
Methanol, water, acetonitrile, DMSO, and formic acid solvents were all HPLC or Trace Metal 
grade and were purchased from Fisher Scientific. Samples were stored in Supelco slit top 2 mL 
vials prior to and during analysis (Fisher Scientific). These were stored at -20 ºC when not in use 
and kept at 5 ºC while in the autosampler tray immediately prior to analysis.  
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 uHPLC separations were carried out on a Dionex Ultimate 3000 uHPLC system using a 
BDS Hypersil C18 column (150 x 2.1 mm) with a 2.4 μM particle size (Thermo-Scientific; cat # 
28102-152130). Separations were performed at 2-4 kPa. Mass detection and analyte 
quantification were carried out using a microTOF-Q11 electrospray ionization time-of-flight 
quadrupole mass spectrometer equipped with a heated-electrospray ion source (Bruker).  
Separations were achieved by linear gradient elution transitioning from 100% Solvent A 
(aqueous) to 100% Solvent B (organic) over 20 min, followed by a 3 min run of 100% Solvent B 
and then a return to 100% Solvent A in a final 3 min washing. A flow rate of 0.4 ml/min with a 
column temperature of 50 °C was determined to be optimal for separation using the above 
method. Solvent A: ultrapure water with 0.1 % formic acid; Solvent B: MeOH with 0.1 % formic 
acid. UV spectra were measured over 390-420 nm using the HyStar software package.  
The uHPLC was coupled to an electrospray mass analyzer operating in positive ion 
mode. The spectrometer used a capillary voltage of 4,500 V and capillary temperature of 180°C.  
The nebulizing gas was set at 6.0 L/min. The software used for data analysis was Bruker 
Compass Data Analysis. The microTOF-Q11 instrument is capable of resolving ±0.001 amu mass 
differences. Due to the use of such high resolution, metabolites can be monitored via detection of 
their exact mass (heme parent ion mass: 616.1794 amu). The amounts of metabolites are 
quantified via integration of the corresponding extracted ion chromatogram (EIC) peak and 
comparison of the peak area to standard curves generated for known concentrations of pure hemin 
and internal standard (0.1 – 7 μM) measured at the same time as the analytes. Standard curves 
were generated in both potassium phosphate buffer. An internal standard (2-vinyl-4-
hydroxymethyl-deuteroporphyrin IX) was added to each sample to a final concentration of 0.05 
M in order to compensate for run to run variability and instrument drift, neither of which proved 
to perturb the data substantially. 
Intracellular heme quantification assay using IsdG - S. aureus ∆isdG and ∆hemB bearing a 
plasmid constitutively expressing IsdG (plgt.isdG) were grown overnight (66). Based on 
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stationary phase culture density, ∆isdG and ∆hemB pellets were resuspended with 500 μl and 50 
μl of lysostaphin in TSM buffer (6 μg/ml lysostaphin), respectively. Samples were incubated at 
37°C for 25 min and pelleted by centrifugation at 16,300 x g. ∆isdG and ∆hemB were 
resuspended in 250 μl and 200 μl, respectively, of 100 μM PMSF in SoluLyse (Genlantis). 
Samples were lysed by sonication, normalized by BCA (ThermoScientific), and IsdG quantities 
were assessed as described previously (66). Band density was quantified using the Odyssey 
System software (LI-COR) and arbitrary units were converted to protein concentration based on 
an IsdG standard. 
Statistical analysis - Where indicated, Student’s t-tests were calculated using either Excel 2007 or 
GraphPad Prism 5. Tests of skewness, kurtosis, and D’Agostino and Pearson omnibus normality 
test were calculated using GraphPad Prism 5. When sample sizes were too small to apply 
standard tests for normality, samples were considered to be normally distributed if their skewness 
and kurtosis fell approximately within ±1 and ±3, respectively. Results were considered 
significant if the p-value was less than or equal to 0.05. 
 
Results 
A high-throughput screen identifies activators of HssRS. In order to identify small molecule 
activators of HssRS, a high-throughput screen (HTS) using luminescence as a reporter of HssRS 
activity was performed. The hrtAB promoter was cloned into the pXen-1 vector, which contains a 
luxABCDE operon that produces blue-green light when expressed (Figure 3A). This construct 
was transformed into wildtype S. aureus and the resulting strain was used to screen 
approximately 160,000 small molecules in the Vanderbilt Institute for Chemical Biology’s 
compound library. This primary screen resulted in the identification of 250 positive hits. Based on 
luminescence values, the top 110 hits were subjected to a secondary screen using a xylE reporter 
assay to eliminate compounds that generate non-specific luminescence (90). Hits that passed this 
secondary screen were further tested in a tertiary screen for their ability to adapt S. aureus to 
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heme toxicity by growth curve analyses (90). Of all the compounds screened, ‘882 was the most 
potent activator of hrtAB expression. ‘882 activates the hrtAB promoter in a dose-responsive 
manner requiring HssRS and pre-adapts S. aureus for heme toxicity (Figure 3B and C). These 
properties were observed for both commercially purchased and independently synthesized 
preparations of ‘882 (Figure 3D). These results establish ‘882 as a small molecule activator of the 
HssRS-dependent heme stress response. 
 
‘882 stimulates heme biosynthesis to activate HssRS. To determine the mechanism by which 
‘882 activates HssRS, the residues required for HssS activation by ‘882 were compared to the 
residues required for HssS heme sensing. It was previously determined that residues R94A, 
T125A, and F165A reduce HssS heme sensing to different degrees. The impact of these 
mutations on HssS activation by ‘882 mirrored that observed upon heme exposure (Fig. 4A). This 
result indicates that heme and ‘882 trigger HssS signaling through similar residues despite being 
structurally distinct. 
 This observation suggests that ‘882 stimulates HssRS through a mechanism similar to 
that of heme. A potential explanation is that ‘882 is a small molecule activator of endogenous 
heme synthesis. To test this model, the phrt.xylE reporter plasmid was transformed into the heme 
auxotroph hemB::ermC (∆hemB) and HssRS activation was evaluated upon ‘882 exposure (92). 
In contrast to wildtype S. aureus, ‘882 does not activate HssRS in ∆hemB (Figure 4B). The loss 
of ‘882-mediated activation of HssRS in ∆hemB is not due to the slower growth rate of this strain 
as XylE activity from a constitutively expressed xylE (plgt.xylE) is only modestly decreased 
(Figure 4B). Furthermore, exogenous heme activates HssRS in ∆hemB, indicating that ∆hemB 
HssRS is still able to sense heme (Figure 4C).  
  
19 
 
 
 
 
 
 
Figure 3. A high-throughput screen identifies small molecule activators of HssRS. A. 
160,000 compounds from the Vanderbilt Institute for Chemical Biology small molecule library 
were screened using a luxABCDE reporter gene fused to the hrtAB promoter (phrt.lux). 
Luminescence of S. aureus wildtype (WT) and ∆hssR carrying either promoterless luxABCDE 
(pXen1) or phrt.lux. B. A secondary screen consisting of a XylE reporter assay verified the 
activity of the top 110 hits from the primary screen, including ‘882. Triplicate cultures of S. 
aureus WT and ∆hssR transformed with the hrtAB promoter-xylE fusion-containing plasmid 
(phrt.xylE) were grown in the presence of the indicated additive and XylE activity was measured. 
C. ‘882 was confirmed as the top hit in a tertiary screen that measured the ability of the 
compound to pre-adapt S. aureus for growth in 20 μM heme. Triplicate cultures of WT S. aureus 
were grown overnight in medium containing the indicated additive and sub-cultured into medium 
containing 20 μM heme. Growth was monitored by measuring the optical density at 600 nm 
(OD600) over time. D. The structure of lead compound VU0038882 (‘882). (B and C) Error bars 
represent one standard deviation from the mean. The high-throughput screen was performed by 
DLS and OA. 
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Figure 4. HssRS activation by ‘882 requires HssS residues required for heme sensing and 
endogenous heme biosynthesis. A. S. aureus ∆hssS was transformed with plasmids containing 
the xylE reporter gene fused to the hrtAB promoter and encoding Myc-tagged wildtype HssS 
(HssS-Myc) or HssS-Myc mutated at the indicated extracytoplasmic domain residue (R94A, 
T125A, or F165A). The resulting strains were grown in the presence of the indicated 
concentration of heme (left) or ‘882 (right) and XylE activity was quantified. Triplicate 
experiments were performed and averaged. B. S. aureus wildtype (WT, black lines) and the heme 
auxotroph hemB::ermC (∆hemB, gray lines) were transformed with plasmids constitutively 
expressing XylE (plgt.xylE, dashed lines) or with xylE under the control of the hrtAB promoter 
(phrt.xylE, solid lines). Triplicate cultures of these strains were grown in the presence of ‘882 and 
XylE activity was measured. C. Triplicate cultures of ∆hemB carrying phrt.xylE were grown in 
medium containing the indicated concentration of heme and XylE reporter activity was measured. 
(B and C) Error bars correspond to one standard deviation from the mean. Experiments in A and B 
were performed by DLS.  
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 These observations are consistent with a model whereby ‘882 exposure leads to an 
increase in intracellular heme and subsequent HssS activation. In support of this model, 
intracellular heme levels increase in a dose-responsive manner in bacteria treated with ‘882 
(Figures 5A and B). Moreover, ‘882 exposure leads to a darkening of S. aureus pellets indicative 
of massive heme accumulation in these cells (Figure 5A, inset). The activation of HssS by ‘882 is 
not due to enzymatic degradation of heme as ‘882 still activates HssS in a strain of S. aureus 
lacking all heme oxygenases (Figure 5C) (66). 
 To determine if the endogenous heme produced as a result of ‘882 exposure is available 
for use in cellular processes, cytoplasmic heme availability was measured by quantifying 
intracellular levels of the cytoplasmic heme oxygenase IsdG. In the absence of exogenous heme, 
IsdG is rapidly degraded; however, heme binding stabilizes IsdG and reduces its proteolytic 
degradation (66). Therefore, the abundance of IsdG reflects the cytoplasmic levels of heme. 
Following ‘882 treatment, the intracellular abundance of IsdG increased in a dose-dependent 
manner (Figures 5D and E). IsdG is not stabilized when S. aureus ∆hemB is grown in the 
presence of ‘882, demonstrating that stabilization of IsdG requires endogenous heme (Figures 5D 
and E). Moreover, IsdG abundance increases in ∆hemB exposed to exogenous heme, indicating 
that heme-dependent stabilization of IsdG is not generally disrupted in this strain (Figures 5D and 
E). Taken together, these experiments reveal that ‘882 exposure increases cytoplasmic heme 
availability. 
 To test whether other bacterial heme sensing proteins monitor endogenous heme, the 
ability of the Corynebacterium diphtheriae ChrAS and Staphylococcus haemolyticus HssRS 
TCSs to sense ‘882 by adaptation growth curve was examined (73, 85, 90). Due to the slow 
growth and low optical density achieved by C. diphtheriae, enumerating CFUs, a more sensitive 
measure of growth, was used to assess the adaptation of this pathogen. Pre-treatment of both 
species with either heme or ‘882 improved survival in heme as compared to non-adapted cultures 
(Figures 6A and B). These data suggest that ‘882 may stimulate heme biosynthesis in multiple 
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Gram positive bacteria and support the hypothesis that the ability to respond to both endogenous 
and exogenous heme is a conserved function of bacterial heme sensor systems. 
 
‘882 diminishes fermentative activity of S. aureus. To define the mechanism by which ‘882 
manipulates heme biosynthesis, a S. aureus transposon library was screened for mutants unable to 
sense ‘882 or heme by growth curve adaptation (90, 99). Of the approximately 7,000 mutants 
screened, only one strain was completely unable to be pre-adapted for heme toxicity by ‘882; this 
strain contained a transposon in the hemL gene involved in heme biosynthesis. Forty-four 
additional mutants were found to have a defect in ‘882 sensing and of those, 17 were also 
deficient in heme sensing (Table 1). A number of genes required for sensing heme and/or ‘882 
are involved in central metabolic pathways including a predicted α-D-1,4-glucosidase (malA), the 
catabolite control protein (ccpA), respiratory response TCS (srrAB), branched-chain amino acid 
amino transferase (ilvE), bifunctional pyrimidine regulator/uracil phosphoribosyltransferase 
(pryR), and pyridoxal 5'-phosphate synthase glutamine amidotransferase subunit (pdxT) (19, 52, 
80). Consistent with these observations, bacteria treated with ‘882 had reduced glycolytic activity 
as indicated by slower acidification of the medium that correlated with delayed consumption of 
D-glucose and reduced production of L- and D-lactate (Figure 7). These observations suggest that 
as ‘882 induces endogenous heme biosynthesis, it also reduces the glycolytic or fermentative 
capacity of S. aureus. These results support a model whereby the metabolic state of S. aureus and 
heme homeostasis are functionally interconnected. 
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Figure 5. ‘882 treatment stimulates endogenous heme biosynthesis. A. Heme levels in 
triplicate cultures of S. aureus treated with the indicated additive were quantified using the 
pyridine hemochromogen assay and normalized to the concentration of protein in the whole cell 
lysates. Inset: Pellets from a culture grown with 40 µM ‘882 are red-brown when compared to 
vehicle treated S. aureus. B. Exact-mass mass spectrometric analysis was used in conjunction 
with UPLC to detect and quantify heme in protoplasts from cells treated with 40 µM ‘882 or 
vehicle grown in triplicate. Measured heme molecules were referenced to estimated CFUs per 
pellet, factoring in dilutions. Dead or lysed cells would also contribute to the measurement. 
Hence the measured numbers are considered upper estimates. Samples measured in duplicate or 
triplicate injections had typical errors of <5% between analytical replicates. Significance was 
calculated using a two-tailed Student’s t-test. C. Triplicate cultures of ΔisdGΔisdI S. aureus were 
grown overnight in medium containing the indicated additive and sub-cultured into medium 
containing 10 μM heme. Growth was monitored by measuring the optical density at 600 nm 
(OD600) over time. Error bars represent one standard deviation from the mean. D. IsdG 
stabilization was used as a reporter for intracellular heme levels. S. aureus ∆isdG (black bars) and 
∆hemB (gray bars) were transformed with plasmids that constitutively express IsdG (plgt.isdG). 
These strains were grown in the presence of the indicated additive. Whole cell lysates, along with 
an IsdG standard, were blotted with anti-IsdG polyclonal antisera. Intracellular levels of IsdG 
were quantified using densitometry. Shown is the average of at least four replicates. Statistics 
were calculated using a two-tailed, Student’s t-test. E. Representative blots of the ∆isdG (top) and 
∆hemB (bottom) data shown in D. In all instances error bars represent one standard deviation 
from the mean. Data in B was generated by SS. 
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Figure 6. ‘882 pre-adapts other Gram positive bacteria for heme toxicity. A. Adaptation by 
heme and ‘882 in Corynebacterium diphtheriae was tested by growth analyses. Triplicate cultures 
were grown overnight in medium containing vehicle, 5 µM heme or 50 µM ‘882 and subcultured 
into medium containing 15 μM heme. The CFUs were enumerated 2.5 h after inoculation and 
normalized to cultures unexposed to heme. Shown is the average of five replicates; error bars 
represent standard error of the mean and significance was determined by a two-tailed Student’s t-
test. B. Adaptation by heme and ‘882 in Staphylococcus haemolyticus was tested by growth 
analyses. Triplicate cultures were grown overnight in medium containing the indicated additive 
and subcultured into medium containing 30 μM heme. Growth was monitored by measuring the 
optical density at 600 nm (OD600) over time. Error bars represent one standard deviation from the 
mean. 
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Table 1: Transposon mutants less sensitive to ‘882 
Tranposon ID Integration site Newman Gene name Gene description 
Co-factors         
11e11*,1 555437-8 NWMN_0482 pdxT pyridoxal 5’-phosphate biosynthesis 
21D1  1728844-5 NWMN_1561 hemL glutamate-1-semialdehyde aminotransferase 
Carbohydrates         
6E11 755114-5 NWMN_0672    aldo/keto reductase family protein  
33F2, (66E5, 
68B5, 68E8)2, 
67E11 
1583073-4, 1584195-6, 
1584189-90 NWMN_1414 malA α-D-1,4-glucosidase  
Cell wall         
52A8  1443696-7 NWMN_1310  alr2  alanine racemase 2 
51C3  1444887-8 NWMN_1311    lysA diaminopimelate decarboxylase 
50 G5 1513348-9 NWMN_1349   ald alanine dehydrogenase 
Amino acids & proteins       
(24B2, 27D3, 
24H6)* 595672-3 NWMN_0516   ilvE 
branched-chain-amino-acid 
aminotransferase 
75D6  1610144-5 NWMN_1439   gcvPB glycine cleavage system P protein, subunit 2  
6F8  1678876-7 NWMN_1513    peptidase U32 family protein
DNA & RNA         
8D8  1614867-8 NWMN_1446  
competence protein ComGC-
like protein 
6H6  1659859-60 NWMN_1490  
DNA internalization-related 
competence protein 
ComEC/Rec2 
4E5, 5B10, 14D7, 
18G5, 51G4* 
1628735-36, 1629189-
90,1629015-6, 
1629152-3, 1628880-1
NWMN_1461  
ATP dependent RNA helicase 
DEAD/DEAH box family 
protein 
76C11  1660941-2 NWMN_1491   
competence protein ComEB 
required for DNA binding 
and uptake 
17B7*  1681514-5 NWMN_1517   
conserved hypothetical 
protein  
2F2* 2296289-90 NWMN_rRNA15 23S rRNA 
Transporters         
11B6, 12F8* 982508-9, 982803-4 NWMN_0886   
Hypothetical protein; 
transporter; next to murGE  
(66C5, 69D11) 1670973-4 NWMN_1505   hypothetical protein contains NRAMP domain 
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Table 1 cont’d: Transposon mutants less sensitive to ‘882 
Tranposon ID Integration site Newman Gene name Gene description 
Regulators         
63C6 736803-4 NWMN_0655    MarR family protein  
48F5* 756768-9 NWMN_0674   saeS S. aureus accessory element histidine kinase 
44C2*  1213708-9 NWMN_1109   pryR pyrimidine operon regulatory protein, 
10D6*  1569662-3 NWMN_1399  srrB   staph respiratory response histidine kinase 
32G6* 1461723-4 NWMN_1328  response regulator 
31H6*  1813162-3 NWMN_1629  ccpA  catabolite control protein A  
Phage         
33G8 1124401-2 NWMN_1026    
conserved hypothetical 
protein; identical to ORF040 
of Bacteriophage 53  
66F2  1990835-6 NWMN_1776    conserved hypothetical protein  
Hypothetical and intergenic       
69E5 780077-8 NWMN_0695/0696 intergenic 
Hypothetical protein (similar 
to MDR transporter) and di-
/tripeptide ABC transporter  
9F8*  846026-7 NWMN_0751   promoter hypothetical protein  
49G8  1060937-8 NWMN_0955/0956 intergenic conserved hypothetical proteins 
50F8  1624756-7 NWMN_1457/sodA intergenic 
Zn specific metalloregulatory 
protein and superoxide 
dismutase Mn/Fe family 
protein 
8G6  1668046-7 NWMN_1502/1503 intergenic hypothetical protein and enterotoxin family protein 
77D12 1670682-3 NWMN_1504   promoter hypothetical protein 
46B9 1690951-2 NWMN_1524    aminotransferase, class V 
52F2  1755385-6 NWMN_1584  promoter hypothetical protein 
2F9  1931846-7 NWMN_1732    hypothetical protein 
52B8  2137622-3 NWMN_1930    hypothetical protein 
52G4  2270169-70 NWMN_2051/ 52 intergenic lytic regulatory protein and truncated resolvase 
32C7* 2384526-7 NWMN_2161   
conserved hypothetical 
protein 
1An asterisk denotes mutants that are less sensitive to both heme and ‘882. 
2Mutants grouped in parentheses reflect identical integration sites. 
  
27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. ‘882 diminishes fermentative activity. S. aureus was grown in triplicate under aerobic 
conditions in the presence of vehicle (black lines) or 40 µM ‘882 (gray lines). At the indicated 
time intervals, culture supernatants were sampled and the A. pH, B. D-glucose, and C. D- and L-
lactate were quantified. Error bars represent one standard deviation from the mean. 
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The metabolic state of the cell impacts heme biosynthesis. To test whether heme biosynthesis 
interfaces with central metabolism, the effect of 2-deoxyglucose (2dG) on heme biosynthesis was 
assessed. The glucose analogue 2dG primarily inhibits the phosphoglucoisomerase reaction, the 
second step in glycolysis (97). Treatment of S. aureus with 2dG reduces endogenous heme levels 
and antagonizes ‘882 activity (Figure 8A). Deletion of 6-phosphofructokinase (pfkA), the third 
enzyme in glycolysis, results in a loss of glucose uptake and decreased acid end product secretion 
in S. aureus (Figures 8B and C). In agreement with the effect of 2dG on heme biosynthesis, both 
basal and ‘882-induced heme biosynthesis are suppressed in ΔpfkA (Figure 8D). These data 
implicate a product of glycolysis in coordinating heme biosynthesis, strengthening the observed 
link between the regulation of heme biosynthesis and central metabolism. 
 
Discussion 
 Here, we describe an HTS that identified small molecule activators of the S. aureus heme 
sensor system HssRS. The most potent hit, ‘882, increases endogenous heme levels and activates 
HssRS through the heme biosynthesis pathway. This effect appears to be due to a perturbation of 
the metabolic state of S. aureus as transposon insertions targeting genes involved in metabolism 
contribute to the ability of the bacteria to sense ‘882. This hypothesis is supported by the 
observations that ‘882 reduces fermentative processes and that inhibiting upper glycolysis 
suppresses endogenous heme biosynthesis. Finally, we have shown that ‘882 activates heme 
sensing systems in other Gram positive pathogens as it pre-adapts C. diphtheriae and S. 
haemolyticus for heme toxicity. 
 Employing ‘882 as a probe has revealed that HssRS responds to both exogenous and 
endogenous heme accumulation. It was previously thought that HssS was stimulated by heme in 
the extracellular environment. Data presented here reverses this model as increased levels of 
endogenous heme activate HssS. This indicates that the ligand sensing domain of HssS is most 
likely intracellular or membrane localized.   
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Figure 8. Glycolytic activity regulates heme biosynthesis. S. aureus was grown in triplicate in 
the presence of vehicle or 10 µM ‘882. Heme levels were quantified using the pyridine 
hemochromogen assay and normalized to the concentration of protein in the whole cell lysates. A. 
Cultures were treated with the indicated dose of 2-deoxyglucose (2dG). (B-C). Wildtype (WT) 
and ΔpfkA Newman cultures were sampled during growth and the absorbance at 660 nm 
measured. B. Glucose levels in supernatants were quantified and used to calculate the rate of 
glucose import [∆glucose (mM/hr)/∆absorbance (OD660/hr)]. C. The pH of the supernatants was 
measured. (B and C) Data collected in three independent experiments are shown. Error bars 
represent twice the standard error of the mean (n = 3). D. Wildtype (WT) and ΔpfkA Newman 
were cultured in TSB+1% pyruvate. # indicates the signal was below the limit of detection. (A 
and D) Error bars represent the standard error of the mean from three independent experiments. 
Statistical significance was determined using an unpaired Student’s t-test. * = p≤0.05, ** = 
p≤0.001, *** = p≤0.0001 Results shown in B and C were performed by NPV. 
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 The discovery that S. aureus monitors intracellular heme status through HssRS suggests 
that other bacterial heme sensing systems may also sense intracellular heme. Already HrtR, which 
functions alone as a transcriptional repressor of hrtRBA in L. lactis, has been shown to monitor 
intracellular levels of heme, but no other TCS HK has been proposed to monitor intracellular 
heme (42). Since ‘882 also adapts C. diphtheriae and S. haemolyticus for heme toxicity and both 
of these species have heme-responsive TCSs, these data suggest that ‘882 also stimulates heme 
biosynthesis in these bacteria and is sensed by their corresponding HKs (73). Furthermore, the 
fact that ‘882 is sensed by C. diphtheriae and S. haemolyticus indicates that the target of ‘882 is 
present in multiple pathogens, establishing this molecule as a powerful probe for studying 
intracellular heme metabolism.  
 The utility of ‘882 as a probe is further supported by the observation that IsdG binds 
endogenously synthesized heme following stimulation with ‘882. There are two families of heme-
degrading oxygenases, the Isd-family and the HO-family which, in addition to liberating iron 
from the protoporphyrin ring of heme, also produce staphylobilin and biliverdin, respectively. 
The HO-family heme oxygenase hemO from P. aeruginosa has previously been shown to bind 
endogenous heme (3). Thus, with data presented here, both families of heme-degrading 
oxygenases have now been shown to target endogenous heme (3). These data implicate a 
potential role for bacterial heme oxygenases in endogenous heme turnover, a result that is likely 
generalizable to all bacterial heme oxygenases (3). In bacteria, heme oxygenases are currently 
thought to primarily function as a mechanism by which exogenous heme may be used as an iron 
source, although a couple of heme oxygenases, specifically, B. anthracis IsdG and Neisseria 
gonorrhoeae HemO, have also been implicated in alleviating heme toxicity (75, 100).  
 The turnover of endogenous heme by bacterial heme oxygenases highlights several 
intriguing hypotheses. To begin with, it points to the possibility that endogenous heme and iron 
homeostasis may be regulated by bacterial heme oxygenases (51, 66). Furthermore, it begs the 
question of whether there is a physiological function of the heme degradation products 
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staphylobilin and biliverdin. The synthesis of heme requires energy, cellular building blocks and 
reducing equivalents; degrading heme simply to release iron and maintain heme homeostasis 
seems to be energetically inefficient. The functions of the heme oxygenase products (biliverdin 
and staphylobilin) in bacteria remain unclear. In cyanobacteria, algae, and plants, the heme 
degradation product biliverdin is a precursor for light-harvesting phytobilin pigments (20). A 
reaction specific to mammals is the conversion of biliverdin to the potent antioxidant bilirubin 
(47, 88). It is possible that bacterial biliverdin and staphylobilin are excreted as waste products or 
further metabolized to be used as a carbon and nitrogen sources. The energetically economical 
nature of bacteria, however, suggests that it is unlikely that biliverdin and staphylobilin are 
simply refuse. In the context of iron and heme homeostasis, it is possible that biliverdin and 
staphylobilin might function as signaling molecules or somehow provide protection from heme 
toxicity. In order to study these exciting ideas, ‘882 may be used as a probe to dissect the impact 
of endogenous heme metabolism by bacterial heme oxygenases on the regulation of heme uptake 
and biosynthesis, which may reveal a physiological function of heme degradation products. 
 Heme biosynthesis is typically regulated by cellular iron or heme levels, although there is 
some evidence that it is tied to central metabolism (14, 22). The perturbation of heme 
homeostasis and central metabolism by ‘882 suggests that the two cellular processes are 
coordinated in S. aureus. Strengthening this hypothesis, both chemical and genetic inhibition of 
the upper steps in glycolysis result in suppressed basal and ‘882-induced heme levels. These data 
suggest that an intact glycolytic pathway is required for ‘882-dependent activation of heme 
biosynthesis, further supporting a functional interconnection between central metabolism and 
heme biosynthesis in S. aureus. Since inhibiting upper glycolysis suppresses endogenous heme 
biosynthesis and repressing fermentation stimulates endogenous heme biosynthesis, this suggests 
that a metabolic signal between upper glycolysis and fermentation coordinates heme biosynthesis. 
The opposing effects on heme homeostasis observed upon targeting upper glycolysis and 
fermentation suggest that when upper glycolysis is inhibited, a metabolic signal is depleted versus 
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when fermentation is repressed, a metabolic signal accumulates. In this way heme biosynthesis 
could be functionally tied to the energetic flux of the cell. An integration of heme homeostasis 
with central metabolism is consistent with the fact that heme and iron are critical co-factors for 
many enzymes involved in energy homeostasis. Further studies employing ‘882 could dissect the 
interplay between heme and central metabolism in both S. aureus and other pathogens. 
 In summary, we have identified a small molecule that diminishes fermentative processes 
in S. aureus, stimulates endogenous heme biosynthesis and activates HssRS. This molecule has 
proven to be valuable as a probe of bacterial heme homeostasis. Tools for stimulating endogenous 
heme biosynthesis are limited and these probes, which stimulate heme biosynthesis across genera, 
will provide insight into conserved mechanisms of heme regulation. The effect of ‘882 on 
suppressing fermentative processes does suggest that ‘882 may have therapeutic efficacy in 
environments where S. aureus is forced to rely on fermentation. The potential utility of ‘882 as a 
new therapeutic strategy is addressed in the next chapter. 
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CHAPTER III 
 
THERAPEUTIC POTENTIAL OF ‘882 FOR THE TREATMENT OF  
PERSISTENT INFECTIONS 
 
Introduction 
 Small colony variants (SCVs) of S. aureus are spontaneous, slow-growing mutants 
associated with persistent and recurrent S. aureus infections that are recalcitrant to antibiotic 
therapy (63). Their slow growth is often due to lesions that eliminate respiration, such as 
inactivation of MK or heme biosynthesis. SCVs are not exclusive to S. aureus as they have been 
isolated in other pathogens, including Escherichia coli, Neisseria gonorrhoeae, Pseudomonas 
aeruginosa, and Salmonella enterica serovar Typhimurium (6, 63). 
 The two prototypical disease states associated with S. aureus SCVs are cystic fibrosis 
(CF) and osteomyelitis. Both diseases typically involve prolonged infection and antibiotic 
treatment. In CF, S. aureus is usually isolated from complex microbial infections that primarily 
include P. aeruginosa. P. aeruginosa secretes several antibacterial compounds including 
pyocyanin, which inhibit bacterial respiration. Since SCVs do not have a functional respiration 
branch for energy production, they can resist assaults from P. aeruginosa, the host immune 
response, and antibiotic treatment. One study analyzed the sputa from 72 CF patients and found 
that 70% are chronically colonized with S. aureus and, of those samples, 46% contained SCVs 
(35).  The deep-tissue infections associated with S. aureus osteomyelitis require prolonged 
antibiotic treatment as the blood flow is restricted to the site of infection. Therefore, analogous to 
CF, osteomyelitis tends to select for SCV persister populations. This is evidenced by the 
identification of S. aureus SCVs in approximately 29% of patients with S. aureus osteomyelitis 
(91). In this study, S. aureus SCVs were only isolated from the patients who had previously 
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received gentamicin bead therapy at the site of infection; these patients were prone to recurrent 
osteomyelitis. 
 SCVs are intrinsically resistant to antibiotics and host defenses primarily because their 
respiratory branch is inactive. The loss of respiration results in a low ∆ψ across the membrane 
(39). Both aminoglycosides, such as kanamycin and gentamicin, as well as antibacterial cationic 
peptides require ∆ψ to cross the bacterial envelope. Therefore SCVs are intrinsically resistant to 
aminoglycosides and some host defense peptides. Furthermore, the slow growth of SCVs also 
results in reduced cell wall production, which makes the bacteria less susceptible to cell wall 
targeting antibiotics such as β-lactams (64).  
 The host-pathogen interaction is complex and it is likely the metabolic flexibility of S. 
aureus which enables this microbe to be a successful pathogen. Abscesses, which are purulent 
lesions containing bacteria and neutrophils surrounded by a pseudocapsule, are a hallmark of S. 
aureus infections (11). Upon encountering S. aureus, the neutrophil releases a toxic milieu of 
chemicals to kill the invading pathogen. One component of this toxic milieu is nitric oxide (NO·), 
which inactivates iron-containing proteins critical for respiration (69). When S. aureus relies on 
fermentation, NO· no longer has a negative effect on growth (69). Therefore it is likely that 
fermentation is critical to staphylococcal pathogenesis since abscesses are thought to be anaerobic 
environments and S. aureus can persist in that niche (59). 
 In Chapter II it was determined that ‘882 suppresses fermentative processes such as 
glucose uptake and acid end product excretion. This suggests that ‘882 may be toxic to 
fermenting S. aureus, including clinically relevant SCVs. In the following chapter this hypothesis 
is tested and the potential utility of a small molecule inhibitor of fermentative growth is 
elaborated.  
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Methods 
Bacterial strains and growth conditions- Staphylococcus aureus strains Newman, ∆hssRS, 
∆menB, and ∆isdG have been described previously (16, 51, 83, 90, 93). S. aureus hemB::ermC 
(∆hemB) has been described previously and was transduced into Newman using bacteriophage Φ-
85 (51, 92). Corynebacterium diphtheriae strain HCL2 was used. 
 All S. aureus strains were grown on tryptic soy agar (TSA) containing 10 µg/ml 
chloramphenicol when appropriate and grown at 37°C for 20-30 h. All overnights were grown in 
5 ml of tryptic soy broth (TSB) at 37°C with shaking at 180 rpm unless otherwise noted. All 
aerobic growth conditions were at 37°C with shaking at 180 rpm in TSB unless otherwise stated. 
Anaerobic growth was obtained by growing cultures in 5 ml of TSB in aeration tubes at 
37°C with shaking at 180 rpm for 15 h. Cultures were diluted to a theoretical OD600 of 0.0001 and 
200 µl were added to 5 µl of additive in a 96 well plate. Cultures were placed in an anaerobic jar 
and incubated at 37°C for 18 h. 
Unless stated otherwise, vehicle treatment refers to a volume of DMSO comparable to the 
volume added containing the described compound (‘882 or ‘373). 
XylE reporter assays - XylE assays were performed as described previously with modifications in 
growth conditions (90). The bacteria were grown for 9 h and diluted 1:100 into 0.5 ml of media 
for 15 h. 
Growth curve analyses - Overnight cultures of Newman were diluted 1:100 into 100 μl of media. 
Bacterial cells were incubated and the OD600 was measured at the specified time points. For all 
staphylococcal adaptations, cultures were inoculated in 0.5 ml of TSB for 1 h at 37°C, 180 rpm 
and sub-cultured 1:100 in 100 ul of media containing the indicated additive. Cultures were pre-
adapted overnight and analyzed as described above for a typical growth curve. 
Gentamicin resistance assay - An overnight of Newman grown on a Cel-Gro Tissue Culture 
Rotator (Lab-Line) was sub-cultured 1:100 into 5 ml of TSB containing the indicated additive 
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(gentamicin, 10 μg/ml; ‘882, 20 μM) and growth on the rotator was continued for 24 h. CFUs 
were enumerated on TSA and TSA containing 5 μg/ml gentamicin. 
Neutrophil killing assay - All mice were maintained in compliance with Vanderbilt’s Institutional 
Animal Care and Use Committee regulations. Polymorphonuclear leukocytes (PMNs) were 
elicited using casein and harvested from 13-16 week old male C57BL/6 mice (Jackson Labs) as 
previously described (36). Bacteria were prepared and assayed as previously described with 
modifications (36). An overnight of Newman grown on a Cel-Gro Tissue Culture Rotator (Lab-
Line) was sub-cultured 1:100 and grown in the rotator to mid-log. Following growth, the bacteria 
were resuspended to an OD600 of 0.4 in phosphate buffered saline (PBS) and 1 ml of culture was 
pelleted. The pellet was incubated in 50% normal mouse serum, 50% RPMI/H (10 mM HEPES in 
RPMI), 10 μM MnCl2 and either vehicle or 40 μM ‘882 for 30 min. The pellet was resuspended 
in 1 ml RPMI/H with 20 μM MnCl2 and 2X vehicle or ‘882. 
NO· growth curve - 1 ml of an overnight of Newman grown at 37°C, 250 rpm was washed with 
PNG (PN media with 0.5% glucose) (60). The cultures were diluted to an OD660 of 0.01 in PNG 
and 200 µl were aliquoted into a 96 well plate. The plate was incubated at 37°C with shaking (14 
min 30 sec 1 mm Orbital, 30 sec 1 mm Linear) on a Tecan Infinite F200Pro. When the cultures 
reached an OD660 of 0.15, NO· was added with a final concentration of 10 mM NOC-12 and 1 
mM DEANO. 
C. diphtheriae growth curve  - C. diphtheriae was grown aerobically in brain heart infusion (BHI) 
medium for 20 h at 37°C, 180 rpm. The cultures were back-diluted in BHI to a theoretical OD600 
of 0.0001 and 150 µl of bacterial culture were added to 5 µl of ‘882 stock. Cultures were grown 
at 37°C, 180 rpm for 18 h and the OD600 measured. 
Systemic murine model of infection - All mice were maintained in compliance with Vanderbilt’s 
Institutional Animal Care and Use Committee regulations. Seven week old BALB/c (Jackson 
Laboratory) female mice were infected retro-orbitally with 2x107 CFU of Newman as described 
previously (77). ‘373 was prepared in 10% Tween 80 and brought to a neutral pH with 0.1 M 
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sodium hydroxide. Intraperitoneal (IP) treatments were given 2 h before infection and every 
subsequent 24 h until the mice were euthanized with CO2 96 h post-infection. Liver abscesses and 
CFUs were enumerated. 
Imaging MALDI-MS/MS - Livers from mice infected and treated as described above were 
harvested 24 h post infection (1 h after the 2nd treatment) and flash frozen on hexane and dry ice. 
Ten μm sections were prepared using a cryostat and thaw-mounted directly to a gold-coated 
stainless steel MALDI target plate (Applied Biosystems). 30 mg/ml of 2,5-dihydroxybenzoic acid 
(DHB) was prepared in 1:1 acetonitrile:water with 0.1% trifluoroacetic acid. Matrix was applied 
using a thin layer chromatography glass reagent sprayer (Kontes Glass Company). 
 Mass spectra were acquired in positive-ion MS/MS mode using a MALDI LTQ XL linear 
ion trap mass spectrometer (Thermo Scientific) equipped with 337-nm nitrogen laser operating at 
60 Hz. Two in-line neutral density filters were used. Protonated ‘373 molecules (m/z 255.2) were 
isolated and fragmented with Helium gas serving as the trapping and collisional gas. Ion density 
images were extracted from the raw data using ImageQuest version 1.0.1 (ThermoScientific). 
‘373 Quantitation via HPLC - Levels of ‘373 in liver tissue analyzed via Imaging MALDI-
MS/MS (IMS) were quantified using HPLC-MS/MS. Tissues were homogenized in 1:1 
acetonitrile:methanol manually using a pestle and a Model 100 Sonic Dismembrator (Fisher 
Scientific). Homogenate was diluted to a final concentration of 20 mg/ml, and cellular debris was 
removed by centrifugation at 3,000 rpm for 5 min. Infected, untreated control liver was 
homogenized to serve as a blank and to prepare calibration standards. 
 Deferasirox (AK Scientific, INC.) was used as an internal standard and was spiked at a 
concentration of 100 pg/ml into the supernatant solution of all samples analyzed. A calibration 
series of ‘373 was spiked into control tissue supernatant at concentrations of 0, 7, 50, 100, 150, 
and 200 ng/mL.  
 Separations were performed on a 1260 Infinity HPLC system (Agilent Technologies) 
with a 6430 Triple Quadrupole Mass Spectrometer (Agilent Technologies) using a ZORBAX 
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Rapid Resolution High Definition SB-C18 column (2.1mm id × 50 mm, 1.8μm). Analytes were 
eluted over 15 min using the following gradient: initial flow 50% Solvent A (0.1% formic acid in 
water) and 50% Solvent B (0.1% formic acid in 1:1 acetonitrile:methanol) for 30 seconds, ramped 
to 80% Solvent B over 10 min, held for an additional min, ramped back to 50% Solvent B over 3 
min, and held for an additional min.  
 Optimal parameters for transitions were determined using Mass Hunter optimizer version 
B.04.01 (B4114). Four transitions were monitored for both the target of interest and the internal 
standard. For ‘373, a precursor [M+H]+ of 255 was monitored at a retention time of 4.7 min for 
transitions to 122 for quantitation and 65, 102, and 190 as qualifiers. For Deferasirox, a precursor 
[M+H]+ of 374 was monitored at a retention time of 5.0 min for transitions to 120 for 
quantitation and 65, 108, and 182 as qualifiers. Data were analyzed using Mass Hunter 
workstation software Quantitative Analysis version B.04.00/build 4.0.225.19. Calibration curves 
were generated as response ratios of ‘373 relative to the internal standard and had an R2 value of 
0.996. 
Statistical analysis - Where indicated, Student’s t-tests were calculated using either Excel 2007 or 
GraphPad Prism 5. Tests of skewness, kurtosis, and D’Agostino and Pearson omnibus normality 
test were calculated using GraphPad Prism 5. When sample sizes were too small to apply 
standard tests for normality, samples were considered to be normally distributed if their skewness 
and kurtosis fell approximately within ±1 and ±3, respectively. Results were considered 
significant if the p-value was less than or equal to 0.05. 
 
Results 
‘882 is bacteriostatic to fermenting S. aureus. The ‘882-dependent suppression of substrate 
level phosphorylation in aerobic cultures suggests that the compound may inhibit fermentative 
growth. Indeed, when S. aureus was grown anaerobically in the presence of ‘882, growth was 
dramatically reduced (Figure 9A). In addition, a strain bearing a lesion in the MK biosynthesis 
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gene menB (∆menB), which cannot respire and solely ferments to produce energy, is more 
susceptible to ‘882 toxicity than wildtype (Figure 9A). ‘882 is bacteriostatic to ∆menB both 
aerobically and anaerobically (Figure 9B). Moreover, when ‘882 is combined with the respiratory 
poison potassium cyanide (KCN), S. aureus growth is inhibited, even under aerobic conditions 
(Figure 9C). Taken together, these data indicate that ‘882 inhibits S. aureus fermentative growth 
and that respiration is protective against ‘882 toxicity. Notably, ‘882 inhibits the growth of C. 
diphtheriae, supporting the conserved activity of ‘882 in heme sensing organisms (Figure 9D). 
Furthermore, ∆hemB, an SCV deficient in heme biosynthesis, is also sensitive to ‘882, indicating 
that heme accumulation is not the source of toxicity, but rather a result of ‘882 perturbing S. 
aureus metabolism (Figure 9A). 
 
‘882 prevents the evolution of antibiotic resistance. S. aureus SCVs are obligate fermenters 
that emerge in response to aminoglycoside treatment (63). The sensitivity of fermenting S. aureus 
to ‘882 lead to the hypothesis that this compound could prevent the outgrowth of antibiotic 
resistant SCVs in the presence of aminoglycosides. To test this, S. aureus was grown in the 
presence of vehicle, gentamicin, ‘882, or a combination of gentamicin and ‘882, and the evolution 
of gentamicin resistance was monitored. Bacteria treated with gentamicin alone became resistant 
to gentamicin, whereas ‘882 treatment alone did not affect the number of viable or gentamicin-
resistant bacteria (Figure 8). Combining ‘882 with gentamicin resulted in a 5-log reduction in 
bacterial viability and eliminated all detectable gentamicin-resistant colonies (Figure 10). This 
suggests that targeting fermentation can be used as an adjunctive therapy with antibiotics that are 
active against respiring S. aureus to improve antibacterial action and reduce the emergence of 
antibiotic resistance.  
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Figure 9. ‘882 inhibits fermenting S. aureus. A. S. aureus wildtype (WT, dashed lines), the 
menaquinone auxotroph (∆menB, dotted lines), and the heme auxotroph hemB::ermC (∆hemB, 
solid lines) were grown in triplicate under aerobic (aer, black lines) and anaerobic (ana, gray 
lines) conditions in the presence of the indicated log of the concentration of ‘882 (µM). After 18 
h the absorbance at 600 nm (OD600) was measured and normalized to vehicle (DMSO) treated 
bacteria. Curves were fit by nonlinear regression analysis and absolute logIC50 values were 
calculated in Prism with the top set at 1.0 and the bottom set at 0.15. LogIC50 values are indicated 
in parentheses in the figure key +/- standard error of the mean. All logIC50 values were 
statistically different from WT aerobic logIC50 when analyzed by one-way ANOVA with a 
Dunnett post test (p<0.001). Error bars represent the standard error of the mean. B. CFUs from A 
were enumerated at the beginning and end of the time course for bacteria treated with vehicle and 
40 µM ‘882. The fold increase over the input of bacteria was determined. C. Triplicate cultures of 
S. aureus were grown in the presence of vehicle (DMSO), 1 mM potassium cyanide (KCN), 40 
µM ‘882, or a combination of 1 mM KCN and 40 µM ‘882. Growth was monitored by measuring 
the OD600 at the indicated time points. D. Triplicate cultures of C. diphtheriae were grown in the 
presence of the indicated concentration of ‘882. Growth was measured by OD600 at 18 h. Shown 
is the average of three independent experiments. Error bars in panels B-D represent one standard 
deviation from the mean.  
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Figure 10. Co-treatment of S. aureus with ‘882 and gentamicin prevents the outgrowth of 
antibiotic resistant isolates. Triplicate cultures of S. aureus were grown in the presence of the 
indicated additive. After 24 h, CFUs were enumerated on TSA containing 5 μg/ml gentamicin 
and plain TSA with a limit of detection of 100 CFUs/ml (minimum y-value); # indicates colonies 
were not identified above the limit of detection. Shown is the average of three independent 
experiments. Error bars represent one standard deviation from the mean.  
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‘882 enhances innate immune function. Neutrophils are the first immune cells to respond to the 
site of a S. aureus infection (13). As part of the innate defense program, they secrete noxious 
chemicals to kill invading pathogens; this includes NO·, which inactivates respiration (13, 69). In 
agreement with the observation that ‘882 is particularly toxic to fermenting S. aureus, 
simultaneous exposure of S. aureus to ‘882 and NO· is more antibacterial than treatment with 
either molecule alone (Figure 11A). Additionally, ‘882 improves neutrophil-dependent killing of 
S. aureus but does not overtly affect neutrophil viability (Figure 11B). These results support the 
notion that ‘882 may have therapeutic efficacy against bacterial invaders by augmenting the 
killing activity of neutrophils. 
 
A derivative of ‘882 reduces S. aureus pathogenesis in vivo. Abscesses are a hallmark of S. 
aureus infections (11). It is likely that fermentation is critical to staphylococcal pathogenesis 
since abscesses are thought to be anaerobic environments (59). Testing this hypothesis is 
challenging as S. aureus fermentation is branched and is accomplished by multiple parallel-acting 
enzymes, so genetic inactivation of fermentation is impractical. The toxic effect of ‘882 toward 
fermenting S. aureus provides an opportunity to gain initial insights into the role of fermentation 
in pathogenesis. However, ‘882 has a metabolically labile furan group which may form protein 
adducts and deplete glutathione in vivo (7). Thus, the furan was replaced with a 2-fluorophenyl 
group to create a more biologically stable derivative, VU0420373 (‘373) (Figure 12A). ‘373 
activates HssRS as evidenced by its ability to increase the expression of the xylE reporter gene 
and pre-adapt S. aureus for heme toxicity (Figures 12B and C). In addition, ‘373 inhibits the 
growth of S. aureus ∆menB, although to a lesser extent than ‘882 (Figure 12D).  
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Figure 11. ‘882 enhances S. aureus susceptibility to neutrophil killing mechanisms. A. S. 
aureus was grown in the presence or absence of 10 µM ‘882. When the cultures reached an 
optical density at 660 nm (OD660) of 0.15, nitric oxide (NO·) was added to the indicated cultures 
with a final concentration of 10 mM NOC-12 and 1 mM DEANO. B. S. aureus was grown in the 
presence of vehicle (DMSO) or 40 µM ‘882 and coated in serum. Murine PMNs were elicited 
with casein and harvested from the peritoneum. The ability of neutrophils to kill S. aureus in the 
presence of ‘882 was assessed by comparing CFUs recovered from neutrophil-exposed S. aureus 
to those recovered from identical conditions lacking neutrophils. The mean of at least six 
independent experiments performed in triplicate are represented by the data; error bars represent 
standard error of the mean and significance was determined by a two-tailed Student’s t-test. Data 
presented in A were performed by NPV and in B were performed with the assistance of TKF. 
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Figure 12. ‘373 exhibits effects similar to ‘882. A. Shown is the structure of derivative 
VU0420373 (‘373). B. Triplicate cultures of S. aureus wildtype (WT) and ∆hssRS transformed 
with a plasmid containing the xylE reporter gene fused to the hrtAB promoter (phrt.xylE) were 
grown in medium containing the indicated additive. Following growth to stationary phase, XylE 
activity was measured and normalized to lysate protein concentrations. An asterisk denotes the 
value was below the limit of detection. C. Triplicate cultures of S. aureus were grown overnight 
in medium containing the indicated additive. Cultures were back-diluted into medium containing 
20 μM heme. The absorbance at 600 nm (OD600) was taken at the indicated times after 
inoculation. D. S. aureus WT and the menaquinone auxotroph (∆menB) were grown in triplicate 
under aerobic and anaerobic conditions in the presence of vehicle (DMSO) or 40 µM ‘373. CFUs 
were enumerated at the beginning and end of the time course. Based on these values, the fold 
increase over the input of bacteria was determined. (B-D) Error bars represent one standard 
deviation from the mean. ‘882 SAR and ‘373 synthesis was performed by BFD. 
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 Intraperitoneal administration of ‘373 to mice intravenously infected with S. aureus 
resulted in a significant 1-log decrease in CFUs recovered from the livers of ‘373-treated animals 
as compared to vehicle (Figure 13A). Notably, ‘373-treatment reduced tissue pathology 
associated with infection as demonstrated by a significant reduction in the number of liver 
abscesses (Figure 13B). This liver-specific reduction in bacterial burden and inflammation 
correlates with an accumulation of ‘373 in the livers of treated animals as shown by Imaging 
Mass Spectrometry (IMS) (Figures 13C-F) (49). To quantify the tissue level of ‘373, portions of 
the livers were excised and '373 concentrations were determined by HPLC-MS (Figure 13E). A 
linear relationship between tissue level and dose of ‘373 administered was observed. Average 
spectral intensity extrapolated from IMS data of '373 reflected a dose-response relationship 
similar to that observed by HPLC-MS, confirming the suitability of IMS for monitoring tissue 
levels of '373 (Figure 13F). Both the HPLC-MS and IMS data support the notion that the 
therapeutic effect of ‘373 is due to the interaction of the compound with S. aureus as it is found at 
the site where bacterial growth is restricted. Although the therapeutic benefits of ‘373 could be 
due to alternative activities of this molecule, these results provide evidence that targeting 
fermentation in a facultative anaerobe may be a viable therapeutic strategy.  
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Figure 13. ‘373 reduces S. aureus pathogenesis in vivo. Mice infected retroorbitally with S. 
aureus were treated intraperitoneally with vehicle (10% Tween 80) or ‘373. After 96 h mice were 
sacrificed and A. CFUs and B. surface abscesses were enumerated from the livers. Each marker 
represents an individual mouse. Data were collected from three independent experiments 
resulting in n = 13 for vehicle and n = 12 for ‘373-treated mice once the highest and lowest values 
were removed from each group. The horizontal line indicates the mean and the error bars 
represent the standard error of the mean. Statistical significance was determined by a two-tailed 
Student’s t-test. C. Livers from mice treated with the indicated dose of ‘373 were harvested 24 h 
post-infection (1 h after the 2nd treatment), sectioned, and mounted on MALDI target plates. D. 
Tissue sections were imaged by MALDI-MS/MS for accumulation of a fragment of ‘373 by 
MALDI-MS/MS (m/z 255.2134). Spectra were acquired at 10 microscans per step. 5 laser shots 
were acquired per pixel and pixels were obtained every 100 µm. E. Quantitative data from liver 
extract showing an increase in ng of ‘373 per mg liver tissue commensurate to dose. F. Average 
spectral intensity extrapolated from MALDI IMS data (D) for each liver showing a similar dose-
response relationship as observed by HPLC-MS in E. Data presented in panels C-F were 
collected by JMH.  
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Discussion 
 The observation that ‘882 suppresses fermentation suggested that ‘882 would be toxic to 
fermenting S. aureus. This proved true as ‘882 is bacteriostatic to fermenting staphylococci and 
C. diphtheriae. The potential therapeutic utility of targeting fermenting S. aureus was verified as 
‘882 treatment augments innate immune function and prevents outgrowth of antibiotic resistant 
colonies in vitro, and ‘373 treatment reduces S. aureus liver colonization and associated 
inflammation in vivo. 
 The activity of ‘882 against fermenting bacteria has broad therapeutic potential. ‘882 is 
bacteriostatic to SCVs, which often emerge during recurrent and persistent S. aureus infections 
(63). This may be generalizable across other infectious diseases such as N. gonorrhoeae, E. coli, 
P. aeruginosa, and S. Typhimurium which can also spawn SCVs (6, 63). In addition to being 
used as a treatment for persistent infections, derivatives of ‘882 could have utility in 
combinatorial-therapy with antibiotics that target respiring bacteria. As a proof of principle, co-
treating S. aureus with gentamicin and ‘882 in vitro reduces bacterial viability and the outgrowth 
of antibiotic resistant populations. If gentamicin is used to treat S. aureus infections, it is typically 
used in combination with other primary antibiotic agents or conjugated to beads and used as the 
primary antibiotic agent at the site of osteomyelitis infections. SCVs often arise during the 
prolonged antibiotic regimen required for treatment of osteomyelitis. Therefore, it is possible that 
an ‘882-gentamicin dual therapy could be used to improve therapy for osteomyelitis by 
preventing the generation of SCVs during infection. If ‘882 proves synergistic with other primary 
anti-staphylococcal agents such as β-lactams and vancomycin, it is possible that ‘882 could be 
used more broadly as an adjuvant to expand the antibiotic armamentarium that is effective against 
S. aureus infections. 
 The majority of bacterial pathogens use some combination of fermentation and 
respiration to produce ATP, suggesting that both are important for colonization and persistence 
(34). Resisting neutrophil assaults requires S. aureus to rely on fermentation. Adding ‘882 to ex 
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vivo neutrophil-S. aureus mixtures resulted in improved neutrophil killing, suggesting that ‘882 
could augment host defense. In vivo, the importance of S. aureus fermentative pathways during 
infection is demonstrated by the fact that ‘373 reduces abscess formation and S. aureus growth in 
the livers of systemically infected mice. The observed effects of ‘373 on S. aureus pathogenesis 
support the notion that the abscess is an anaerobic environment and that bacterial fermentation is 
required for efficient colonization (59). Furthermore, the modest effect ‘373 has on S. aureus 
pathogenesis in vivo, despite its diminished bacteriostatic activity in vitro, highlights the promise 
of more potent, biologically compatible derivatives of ‘882 as novel therapeutics. 
 In summary, a small molecule has been identified that diminishes fermentative processes, 
stimulates endogenous heme biosynthesis and activates the HssRS heme sensor. This molecule 
has two-fold utility as both a probe of bacterial physiology and an unconventional therapeutic. 
The utility of targeting fermenting bacteria is exemplified by the fact that this compound prevents 
the emergence of antibiotic resistance, enhances phagocyte killing, and reduces S. aureus 
pathogenesis. Compound ‘882 is a powerful tool not only for studying bacterial heme 
biosynthesis and central metabolism but also establishes targeting of fermentation as a viable 
antibacterial strategy. Further studies confirming the mechanisms by which ‘882-derived 
compounds reduce S. aureus pathogenesis and associated inflammation in vivo will lay the 
groundwork for improved strategies for treating recalcitrant infections. 
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CHAPTER IV 
 
A CHEMICAL GENETICS APPROACH FOR DISSECTING THE MECHANISM OF  
‘882-MEDIATED ANTIMICROBIAL ACTIVITY  
 
Introduction 
 Compound ‘882 is toxic to fermenting S. aureus. This has therapeutic utility in either 
mono- or dual-therapy regimens. Understanding the source of ‘882 toxicity in fermenting S. 
aureus will not only elucidate basic mechanisms of S. aureus energy homeostasis, but may also 
identify a cellular target that is sufficient for ablating fermentative growth. Identifying the cellular 
target of ‘882 will enable the activity of ‘882 to be more rapidly improved through structure-
activity relationship (SAR) studies. It may also serve as a platform that would support the 
identification of alternative strategies for targeting fermenting S. aureus.  
 While there are several approaches to target identification, chemical genetics approaches 
undertaken by other groups have successfully identified small molecule targets by isolating 
suppressor mutants (29, 94). If spontaneously ‘882-resistant strains can be identified then their 
genomes can be sequenced to identify genetic lesions that support ‘882 resistance. 
 Here, strains spontaneously resistant to ‘882 toxicity were isolated and characterized. All 
suppressor mutants were found to have deficits in SaeRS function. SaeRS is one of the 16 known 
TCSs in S. aureus. SaeRS is activated by iron and human neutrophil peptides, suppressed by 
heme, and regulates the secretion of exoproteins and other virulence factors (24, 72). The sae 
operon consists of saeP, saeQ, saeR, and saeS. SaeRS functions as a prototypical TCS and SaeP 
and SaeQ enhance SaeS phosphatase activity toward SaeR (32). SaeRS is constitutively 
expressed from the P3 promoter but the P1 promoter drives the expression of all 4 sae ORFs; 
SaeR recognizes P1, therefore SaeRS is autoregulatory (24). S. aureus strain Newman SaeS 
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carries an L18P mutation that increases basal SaeS activation and results in hyperactivity of 
SaeRS in strain Newman compared to other S. aureus isolates (24, 70). It is this hyperactive SaeS 
that is required for ‘882 toxicity in S. aureus. Transcriptional studies of genes regulated by SaeRS 
have provided potential leads to the cellular target of ‘882. These studies employing ‘882 
suppressor mutants have revealed that the SaeRS TCS is required for ‘882 toxicity. Identifying 
the regulatory targets of SaeRS that are the source of ‘882 toxicity will reveal genes essential for 
fermentation, provide guidance for SAR studies, and potentially reveal how energy metabolism 
and heme homeostasis are coordinated. 
 
Methods 
Bacterial strains and growth conditions- Staphylococcus aureus strains Newman wildtype, 
∆saeRS, and saeSP18L have been described previously (16, 46). The USA300 type S. aureus 
clinical isolate LAC cured of erythromycin-resistance (AH1263) was described previously (5).  
 All S. aureus strains were grown on tryptic soy agar (TSA) at 37°C for 20-30 h. All 
overnights were grown in 5 ml of tryptic soy broth (TSB) in aerobic tubes at 37°C with shaking at 
180 rpm unless otherwise noted. Anaerobic growth was obtained by growing cultures in 5 ml of 
TSB in aeration tubes at 37°C with shaking at 180 rpm for 15 h. Cultures were diluted to a 
theoretical OD600 of 0.0001 and 200 µl were added to 5 µl of additive in a 96 well plate. Cultures 
were placed in an anaerobic jar and incubated at 37°C for 18 h. 
Unless stated otherwise, vehicle treatment refers to a volume of DMSO comparable to the 
volume added containing the described compound (‘882). 
Isolation of ‘882 suppressor strains – Triplicate cultures of S. aureus strain Newman were grown 
for 15 h at 37°C, 180 rpm in 5 ml of TSB in aeration tubes. The OD600 of the cultures was 
measured and then the cultures were back-diluted in TSB to a theoretical OD600 of 0.0001. 100 ul 
of the dilute cultures were inoculated onto TSA containing 20 and 40 μM ‘882 and grown under 
anaerobic conditions for 36 h. Each suppressor colony was isolated on TSA and confirmed to be 
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resistant to ‘882 on TSA plates under anaerobic conditions. Each isolate was also tested for 
catalase activity using H2O2 and Gram-stained. All isolates were catalase positive, Gram positive 
cocci. 
Whole genome sequencing of ‘882 suppressor strains – Genomic DNA from Newman wildtype 
and the five ‘882 suppressor strains 20A, 40A, 20-1, 20-6, and 20-11 was purified and 
resuspended to a final concentration of 5 µg in 30 µl of sterile dH2O. It was submitted to the 
Vanderbilt Technologies for Advanced Genomics (VANTAGE) core. Shotgun sequencing was 
performed on an Illumina MiSeq and genomes were assembled using S. aureus Mu50 as a 
reference strain and single nucleotide polymorphisms (SNPs) were reported by VANTAGE. The 
validity of each SNP was determined by comparing the suppressor genomes to the assembled 
Newman genome using the Integrative Genomics Viewer available from the Broad Institute.  
 All SNPs were confirmed by Sanger sequencing. Overlapping regions of approximately 
1,000 bp were amplified by PCR from the genomes of the suppressor strains using the high-
fidelity DNA polymerase Pfu Turbo (Stratagene). PCR products were checked for amplification 
on an agarose gel and column purified using the Qiagen PCR purification kit. DNA was 
sequenced by GenHunter and SNPs confirmed using DNASTAR LaserGene8 SeqBuilder and 
MegAlign programs. 
Hemolysis profiles – Hemolytic profiles of each of the suppressor strains were assessed by 
patching each of the suppressor isolates from TSA to a sheep blood agar plate (BAP). BAP were 
incubated at 37°C for 24-48 h and inspected for zones of clearing. 
Exoprotein profile – Each strain was inoculated from TSA into 15 ml of TSB in a 50 ml conical 
tube and grown for 16 h. Cultures were pelleted at 5,900 x g for 5 min and the supernatants were 
transferred to a clean tube to be stored at -80°C. Samples were later thawed at room temperature 
and syringe filtered through a 0.45 µm membrane. Supernatants were concentrated over a 3 kDa 
column for 60 min at 3,200 x g. Samples were mixed 1:1 with 2X SDS-PAGE loading dye and 
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boiled. 25 µl of each sample was resolved on a 15% SDS-PAGE gel. Proteins were visualized 
using a Coomassie stain. 
anti-SaeQ western blots – Each strain was grown in 5ml of TSB for 15 h under either aerobic or 
anaerobic conditions at 37°C. Anaerobic cultures were sub-cultured 1:50 into 10 ml of TSB 
containing 4 µM ‘882 or an equivalent volume of DMSO and maintained under anaerobiosis. 
Aerobic cultures were sub-cultured 1:100 into 5 ml of TSB containing 40 µM ‘882 or an 
equivalent volume of DMSO and maintained under aerobiosis. All sub-cultures were grown at 
37°C for 8 h and then pelleted at 3,200 x g for 10 min. The supernatants were removed and the 
pellets preserved at -80°C.  
Pellets were subsequently thawed at room temperature and then maintained on ice. Each 
pellet was resuspended in TSM (100 mM Tris-HCl pH 7, 500 mM sucrose, 10 mM MgCl2) with 3 
µl/ml lysostaphin. To compensate for differences in cell density, the aerobic samples were 
resuspended in 500 µl and the anaerobic samples were resuspended in 175 µl. The cell walls were 
removed by incubating all samples at 37°C for 25 min and then centrifugation at 16,100 x g for 
10 min at 4°C. The supernatants were removed and the pellets resuspended in 250 μl of SoluLyse 
Reagent for Bacteria (Genlantis) supplemented with 100 µM phenylmethanesulfonylfluoride 
(PMSF). Each sample was sonicated at 100% for 10 s using a Branson 4c-15 sonicator and 
normalized based on total protein concentration as determined by BCA assay (Pierce). Samples 
were diluted to a final concentration of 3 µg/µl in SDS-PAGE loading buffer, boiled, and 20 µl 
were resolved on a 15% SDS-PAGE gel. Gels were transferred to nitrocellulose membrane for 1 
h at 1000 mA and then blocked overnight at 4°C in 10% non-fat dry milk (NFDM) in tris 
buffered saline (TBS: 50 mM Tris-HCl pH 7.5 and 150 mM NaCl).  
Membranes were probed with 1:2,500 anti-SaeQ antibody for 1 h at room temperature in 
10% NFDM in TBS-T (TBS containing vol/vol 0.01% Tween-20). Membranes were then washed 
3 times in TBS-T. An Alexa fluor 660 goat anti-rabbit IgG (Life technologies) was diluted 
1:6,000 in TBS-T and used as a secondary antibody. Membranes were probed with the secondary 
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antibody for 1 h and then washed 3 times in TBS-T. Western blots were scanned on an Odyssey 
Infrared imaging system (LI-COR). 
RNA preparation and microarray analysis – Strains were cultured anaerobically overnight in 5 
ml TSB at 37°C. Samples were sub-cultured 1:100 into 10 ml of TSB and maintained at 37°C 
under anaerobiosis. At mid-log (5 h after sub-culture), either 10 µl of DMSO or 25 mM ‘882 
(final concentration 25 µM) was spiked into the cultures. Cultures were incubated 10 min at 37°C 
and then mixed with an equal volume of ice cold 1:1 acetone:ethanol and stored at -80°C. All 
samples ranged within 2-6x108 CFU/ml. Replicates were collected on separate days. 
 Samples were thawed on ice and then pelleted at 10,000 x g for 10 min at 4°C. The 
pellets were dried on ice and then resuspended in 500 µl of TE (10 mM Tris-HCl, 1 mM EDTA, 
pH 7.6). Samples were transferred to an RNase/DNase free tube containing Lysing Matrix B 
(MP). Cells were lysed on a FastPrep-24 bead beater for 20 s at setting 5.0, iced for 5 min, and 
then disrupted again for 40 s at setting 4.5. Samples were centrifuged at 16,100 x g for 15 min at 
4°C. The upper phase was transferred to a clean 1.5 ml tube and mixed with 350 µl of RLT for 
every 100 µl of sample resulting in a final volume of approximately 1.5 ml. Samples were 
centrifuged for 15 s at 8,000 x g and the supernatant transferred to a clean tube. 250 µl of ethanol 
was added for every 100 µl of sample. 
 RNA was bound to a Qiagen RNeasy mini column by centrifugation for 15 s at 8,000 x g. 
Each column was washed with 350 µl of RW1 buffer and the flow-through discarded. DNA was 
removed by adding 10 µl DNase I to 70 µl RDD buffer (Qiagen) and incubated on the column for 
20 min at 37°C. Each column was incubated with 350 µl RW1 for 5 min, centrifuged and the 
flow-through discarded. 500 µl of RPE was added to each column then the samples were 
centrifuged and the flow-through discarded; this was performed twice. The column was 
transferred to a clean 1.5 ml tube and the RNA eluted with 40 µl of RNase-free water. 
 Transcriptional changes were analyzed by microarray analysis in the Dunman laboratory 
at the University of Rochester as described previously (4). Two replicates were prepared 
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independently for each condition. Genes with at least a 2-fold change expression, a P-value ≤ 
0.05 as determined by a Student’s t test, and levels detectable above background based on 
Affymetrix algorithms were considered to be differentially regulated. 
 
Results 
‘882-resistant colonies are isolated under anaerobiosis. One strategy employed to identify the 
cellular target that mediates ‘882 toxicity was the isolation of strains spontaneously resistant to 
‘882. If spontaneously ‘882-resistant strains could be isolated, their genomes could be sequenced 
to identify genetic lesions that support ‘882 resistance. To select for ‘882-resistant isolates S. 
aureus strain Newman was grown on TSA plates containing 20 and 40 μM ‘882. The plates were 
grown under anaerobiosis for 36 hours and 15 colonies were identified. Each colony was isolated 
on plain TSA grown aerobically and then patched on plain TSA, 10 and 20 μM ‘882 
anaerobically. Nine of the 15 colonies remained resistant to ‘882 on solid agar under 
anaerobiosis. All nine isolates are catalase positive and appear to be S. aureus by Gram stain. 
These data reveal that S. aureus generates resistance to ‘882 in anaerobic conditions with a 
frequency of approximately 1 in 10-7 CFUs. 
 The genetic stability and heritability of the ‘882 resistance was tested by sequentially 
passing each strain four times at 37°C. After passaging, the nine strains were assessed for ‘882 
resistance in liquid media under anaerobiosis. All passaged strains were resistant to ‘882 (Figure 
14).  
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Figure 14. ‘882-resistance is heritable and stable. Wildtype S. aureus Newman (NM) and 9 
strains isolated on toxic concentrations of ‘882. The first two digits of each name indicate the μM 
concentration of ‘882 from which the colony was isolated. All strains were grown in triplicate, 
aerobically overnight, and back-diluted to a theoretical optical density at 600 nm (OD600) of 
0.0001 in TSB. In a 96 well plate, 200 μl of each diluted culture was added to a stock of ‘882, so 
that the final concentration was 40 μM, or an equivalent volume of DMSO (vehicle). The plate 
was grown in an anaerobic jar and the OD600 was recorded after 18 h of growth. Growth was 
analyzed relative to cultures grown with vehicle alone. Shown are data representative of three 
independent experiments. Error bars represent one standard deviation from the mean. 
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‘882-resistant isolates have genetic lesions in the sae operon. Since the ‘882 resistance of all 
nine isolates is heritable and stable, the identities of the genetic mutations that provide‘882 
resistance were pursued. The genomes of five isolates (20A, 40A, 20-1, 20-6, and 20-11) along 
with the parental Newman strain were sequenced at the VANTAGE core. Shotgun sequencing 
was performed on an Illumina MiSeq and genomes were assembled using S. aureus Mu50 as a 
reference strain. Each strain only had non-synonymous mutations in the sae operon (Figure 15). 
 The obsevation that mutations were only found in the sae operon suggested that the four 
remaining unsequenced strains (20-3, 20-4, 20-7, and 20-8) may also have lesions in the sae 
operon. To test this hypothesis, the sae locus of each strain was amplified by PCR and analyzed 
by Sanger sequencing. Mutations in the sae locus were also identified in 20-3 and 20-8 (Figure 
15). In total, six unique lesions in the sae operon were identified. Isolates 20A and 40A both had 
a point mutation 15 base pairs (bp) 5’ to the saeR translation start site. This could either affect 
saeR expression or mutate SaeQ (G146D). Isolate 20-3 also had a single point mutation, which 
occurs in the TATA box of promoter 1 (P1). Only one isolate, 20-8, had a nucleotide duplication. 
In this strain, 15 bp in the receiver domain of SaeR was duplicated. The three remaining isolates 
20-1, 20-6 and 20-11 all had deletions. Two deletions occurred in the receiver domain of SaeR as 
isolates 20-1 and 20-6 each have unique 9 and 15 bp deletions, respectively. Strain 20-11 has 198 
bp of the DNA binding domain of SaeR deleted. Intriguingly, all mutations either maintained the 
same number of bp in the sae operon or affected the size by a multiple of three. That is, no frame 
shift mutations occurred. The significance of this observation remains to be understood. 
Nonetheless, the clustering of mutations in one regulatory locus of S. aureus Newman suggests 
that the activity of SaePQRS is altered in ‘882-resistant strains and impacts ‘882 susceptibility.  
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Figure 15. Genetic lesions present in ‘882-resistant isolates. The sae locus of nine 
spontaneously ‘882-resistant isolates were sequenced by Sanger sequencing to confirm and 
identify any mutations in the locus. A schematic of the sae locus is depicted above with the two 
promoters (P1 and P3) marked with a bent arrow and the two terminators marked with a hairpin. 
Three isolates: 20-3, 20A, and 40A (orange) had a point mutation. Three isolates: 20-1, 20-6, and 
20-11 (red) had deletions. And one isolate, 20-8, had a 15 base pair duplication. The number 
following the colon denotes the base pair location in the Newman genome affected by the 
mutation. 
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SaePQRS is functionally inactivated in ‘882-resistant mutants. SaePQRS was first identified 
as a S. aureus TCS that regulates the secretion of exoproteins and toxins (25, 26). To examine the 
activity of SaePQRS in ‘882-resistance the hemolytic activity and exoprotein profiles of each 
isolate were visualized (Figures 16A and B). All ‘882-resistant isolates, including those strains 
which have no identifiable genetic lesions in the sae operon, had decreased hemolysis and visibly 
reduced exoprotein abundance. These data suggest that SaePQRS is inactivated in all ‘882-
resistant strains. 
 Since SaePQRS is an autoregulated TCS, inactivating any component of the TCS should 
result in reduced protein abundance of all components of the TCS. In order to determine if SaeRS 
is active in the ‘882-resistant strains, the abundance of SaeQ in each isolate was determined by 
western blot. SaeQ was completely absent in all ‘882-resistant isolates, indicating that each strain 
had a loss of SaePQRS function (Figure 16C). The loss of SaePQRS activity in ‘882-resistant 
strains suggests that an active SaePQRS is required for ‘882 toxicity. 
 
Newman SaeS is necessary for ‘882 toxicity. The observation that all spontaneous ‘882-
resistant strains phenocopied the isogenic saeRS deletion strain (∆saeRS) pointed to the 
hypothesis that a functionally active SaePQRS signaling system is required for ‘882 to be toxic 
under anaerobic growth conditions. To test this hypothesis, the sensitivity of an isogenic saeRS 
deletion strain (∆saeRS) to ‘882 was assessed by anaerobic growth analyses and in fact ∆saeRS is 
resistant to ‘882 (Figure 17). The necessity of SaeRS signaling for ‘882-induced heme 
accumulation and HssRS activation was also assessed. ‘882 still induces heme accumulation and 
HssRS activation even in the absence of SaeRS (data not shown). These data agree with the 
observation that ‘882 is toxic even in the heme biosynthesis deletion strain hemB::ermC and 
strengthen the model that heme is not the cause of ‘882-induced anaerobic growth inhibition. 
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Figure 16. ‘882-resistant isolates have a loss in SaePQRS activity. S. aureus strain Newman, 
Newman ∆saeRS, and 9 isogenic strains resistant to anaerobic ‘882 toxicity were screened for 
SaePQRS function. A. Each strain was spotted onto a sheep blood agar plate and incubated at 
37°C for 24 h. B. All strains were grown overnight in TSB and their supernatants concentrated 
over a 3 kD spin column. Concentrated supernatants were separated on a 15% SDS-PAGE gel 
and visualized using Coomassie dye. C. Whole cell lysates from aerobic cultures were blotted 
with anti-SaeQ antisera. 
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 While determining the toxicity of ‘882 toward other staphylococcal species it was noted 
that ‘882 is not toxic to the prevalent community acquired, methicillin-resistant S. aureus (CA-
MRSA) strain USA300 LAC (Figure 17). Newman SaeS has a single nucleotide point (SNP) 
mutation that switches the amino acid residue at position 18. In most strains, including USA300, 
residue 18 is leucine but in Newman it is proline (24). This mutation results in a hyperactive 
SaeS. Noting that ‘882 is not toxic to USA300 and USA300 does not have the SaeS mutation 
guided the hypothesis that the hyperactive SaeS activity in Newman is necessary for ‘882 
toxicity. To test this hypothesis, Newman SaeS was isogenically converted from proline at 
residue 18 to a leucine (46). This SaeS-repaired strain is not sensitive to ‘882 toxicity under 
anaerobiosis (Figure 17). Together, these data indicate that a hyperactive SaeS is required for 
anaerobic ‘882 toxicity. 
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Figure 17. Newman SaeS is necessary for ‘882 toxicity. Newman (NM) wildtype, ∆saeRS, and 
SaeS P18L (CYL111481), along with USA300 were analyzed for sensitivity to ‘882. Each strain 
was analyzed in triplicate. Overnights were diluted to a theoretical optical density at 600 nm 
(OD600) of 0.0001. Each culture was grown in the presence of vehicle (an equal volume of 
DMSO) and 10 μM ‘882. Cultures were grown at 37°C in an anaerobic jar for 18 h. At the end of 
the time course the cultures were resuspended and OD600 was recorded. Each ‘882 treated culture 
was normalized to the vehicle controls. Error bars correspond to one standard deviation from the 
mean. 
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‘882 and oxygen impact SaeQ abundance. The necessity of Newman SaeS for ‘882 toxicity 
points to the hypothesis that the source of ‘882 toxicity is either SaePQRS or an Sae-regulated 
target. If ‘882 is targeting an Sae-regulated product specifically under anaerobiosis, this suggests 
that oxygen may impact Sae activity. To determine the effect of ‘882 and oxygen on SaePQRS 
activity, SaeQ levels were probed by western blot in both Newman and USA300. 
 In the presence of vehicle alone, growth in an anaerobic environment reduced SaeQ 
abundance in both Newman and USA300. In USA300, however, SaeQ was undetectable, while 
Newman retained a low level of SaeQ (Figure 18). This is in agreement with the report that 
Newman SaePQRS is hyperactive. What is particularly intriguing is that ‘882 treatment increases 
SaeQ abundance under both aerobic and anaerobic conditions in Newman, but suppresses SaeQ 
levels aerobically and does not affect the already absent SaeQ anaerobically in USA300 (Figure 
18). These data suggest that aberrant activation of SaePQRS under anaerobiosis by ‘882 is toxic 
to the bacteria. This leads to two primary hypotheses for the cause of ‘882 toxicity. First, 
SaePQRS over-expression alone under anaerobiosis is stressful to S. aureus. Or second, the effect 
of ‘882 treatment on an Sae-regulated target is the source of toxicity. The latter hypothesis is 
supported by several observations. First, SaeRS regulates many cellular target including genes 
involved in energy homeostasis. Second, SaeRS is a TCS specific to staphylococci, yet ‘882 is 
toxic to non-staphylococcal species (Figure 7). And finally, SaeQ is modestly expressed at basal 
levels in Newman without overt detriment to anaerobic growth suggesting that SaeRS expression 
under anaerobiosis alone is not sufficient to inhibit anaerobic growth.  
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Figure 18. Oxygen and ‘882 impact SaeQ abundance. A. Newman and B. USA300 LAC were 
grown under aerobic and anaerobic conditions for 8 h. Media was supplemented with either 
vehicle (DMSO) or ‘882 (4 μM-anaerobic and 40 μM-aerobic). Whole cell lysates were 
normalized to protein content and resolved on a 15% SDS-PAGE gel. Proteins were transferred to 
a nitrocellulose membrane and probed with anti-SaeQ antibody. 
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Genes differentially regulated by SaePQRS under anaerobiosis. As it seems most likely that 
an Sae-regulated target contributes to anaerobic ‘882 toxicity, identifying the genes differentially 
regulated by SaePQRS under anaerobiosis could reveal the source of ‘882 toxicity. To detect 
genes regulated by SaePQRS S. aureus Newman wildtype and ∆saeRS were grown anaerobically 
to mid-log phase. The samples were pulsed with either vehicle (DMSO) or 10 μM ‘882 for 10 
min. The RNA from these samples was isolated and differential gene expression was analyzed by 
microarray. 
 SaeRS is a major regulatory system in S. aureus so it is not surprising that many genes 
were differentially regulated in the saeRS mutant. The positive regulation of many virulence 
factors, exoproteins and proteases by SaeRS has been well described and were reproduced in our 
microarray (Table 2) (43). The most striking gene clusters regulated by SaeRS were those 
involved in amino acid metabolism (Table 2). Operons involved in cysteine, methionine, 
aspartate, lysine, leucine, isoleucine, valine, glutamate, and histidine metabolism are all positively 
regulated by SaeRS. Transporters of oligopeptides and amino acids are also positively regulated 
by SaeRS. Gene clusters involved in protein synthesis, mevalonate and THF synthesis are 
repressed by SaeRS activity. It is also interesting to note that SaeRS function impacts several 
genes involved in energy homeostasis including two fermentation products: acetoin and lactate. 
 By microarray analysis a total of 81 transcripts were observed to be positively regulated 
by SaeRS. Of these transcripts, 70 are annotated as coding transcripts and 64 are available in the 
Network on Antimicrobial Resistance in S. aureus (NARSA) defined transposon library. Many 
positively regulated gene targets are in shared operons and therefore of the 64 transposon mutants 
available in the NARSA library, 35 are in independent operons. Furthermore, 30 transcripts are 
negatively regulated by SaeRS and 25 of these are annotated to coding transcripts. Of these 25 
genes, 13 are available in the NARSA library and 11 are independent operons. If the exotoxins, 
proteases and other virulence factors are assumed to not be the source of ‘882 toxicity, then there 
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are 36 operons already disrupted in the NARSA defined mutant library that may be the source of 
‘882 toxicity.  
 To begin to dissect the factors regulated by SaeRS that may be the source of ‘882 
toxicity, transposon insertion mutants in these 36 operons of interest will be transduced from the 
NARSA library (USA300 background) into S. aureus strain Newman. Each transductant will then 
be assessed for sensitivity to ‘882 under anaerobiosis. If anaerobic toxicity is due to ‘882 
interacting with a gene positively regulated by SaeRS then the deletion of the target would be 
predicted to result in ‘882-resistance. Alternatively, if ‘882 is causing toxicity through a gene 
repressed by SaeRS then the deletion would be expected to be unable to grow under anaerobic 
conditions. 
 In order to begin investigating the potential role of each operon in ‘882 toxicity, seven of 
these operons have been transduced into S. aureus strain Newman, these include ilvD, oppB, hom, 
asd, NWMN_2616, pknB, and budA1. As a negative control the toxin hlgC was also transduced 
into Newman. Each gene was confirmed to be disrupted by sequencing and then the sensitivity of 
each strain to ‘882 under anaerobic conditions was assessed. None of these eight operons affect 
anaerobic sensitivity to ‘882; although pknB has a modest growth defect under anaerobiosis. It is 
possible that this serine/threonine kinase may contribute to S. aureus sensitivity to ‘882 or 
anaerobic growth in general. The data collected on these eight transposon mutants rule out 
acetoin synthesis, oligopeptide transport, branched chain amino acids, aspartate and lysine 
metabolism as the source of ‘882 toxicity. The involvement of the remaining 29 operons remains 
to be assessed.  
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Table 2: Transcripts regulated by SaeRS under anaerobiosis and ‘882 treatment 
Newman USA300 Fold change Gene name Gene description 
Protein synthesis 
NWMN_1175 SAUSA300_1158 -2.48 - conserved hypothetical protein 
NWMN_1497 SAUSA300_1554 -3.24 - conserved hypothetical protein TIGR00253, RNA binding protein
NWMN_1957 SAUSA300_2002 -2.12 rimJ ribosomal-protein-alanine acetyltransferase, putative 
NWMN_2022 SAUSA300_2072 -2.21 prfA peptide chain release factor 1 
NWMN_2146 SAUSA300_2198 -2.15 rpsC/rplF ribosomal protein L6 
NWMN_2147 SAUSA300_2199 -2.12 rplV ribosomal protein L22 
NWMN_2150 SAUSA300_2202 -2.65 rplW ribosomal protein L23 
Nucleic Acid 
NWMN_0249 SAUSA300_0307 -3.24 - acid phosphatase5-nucleotidase, lipoprotein e(P4) family 
Co-factor Synthesis 
NWMN_0553 SAUSA300_0572 -2.10 mvk/mvaK1 mevalonate kinase 
NWMN_0554 SAUSA300_0573 -2.37 mvaD mevalonate diphosphate decarboxylase 
NWMN_0926 SAUSA300_0959 -2.03 fmt Synthesizes THF and F-met-tRNA 
Cell signaling 
NWMN_0484 SAUSA300_0700/0701 -2.11 ctsR 
conserved hypothetical protein: 
transcription repressor of class III 
stress genes homologue 
NWMN_1130 SAUSA300_1113 -2.08 pknB serine/threonine-protein kinase 
NWMN_1852 SAUSA300_1895 -2.13 - nitric-oxide synthase, oxygenase subunit 
Energy Production 
NWMN_0071 SAUSA300_0129 3.60 - acetoin reductase 
NWMN_0171 SAUSA300_0229 5.05 - propionate CoA-transferase, putative 
NWMN_1616 SAUSA300_1669 2.13 - aminotransferase, class V 
NWMN_1617 SAUSA300_1670 2.16 serA D-3-phosphoglycerate dehydrogenase 
NWMN_2110 SAUSA300_2165 -5.67 budA1 alpha-acetolactate decarboxylase; converts pyruvate to acetoin 
NWMN_2111 SAUSA300_2166 -4.16 budB acetolactate synthase, catabolic 
NWMN_2499 SAUSA300_2537 4.61 ldh L-lactate dehydrogenase 2 
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Table 2 cont’d: Transcripts regulated by SaeRS under anaerobiosis and ‘882 treatment 
Newman USA300 Fold change Gene name Gene description 
Amino acid metabolism 
Cys/Met 
NWMN_0011 SAUSA300_0012 2.60 - homoserine O-acetyltransferase, putative 
NWMN_0348 SAUSA300_0357 2.82 metE 
5-methyl-
tetrahydropteroyltriglutamate-
homocysteine methyltransferase 
(metE) 
NWMN_0351 SAUSA300_0360 2.08 - trans-sulfuration enzyme family protein 
NWMN_0426 SAUSA300_0435 3.28 - 
ABC transporter, ATP-binding 
protein; predicted to transport 
methionine 
NWMN_0427 SAUSA300_0436 3.19 - ABC transporter, permease protein 
NWMN_0428 SAUSA300_0437 3.04 - ABC transporter, substrate-binding protein 
NWMN_2021 SAUSA300_2071 -2.13 - SAM-dependent modification methylase, HemK family 
Asp 
NWMN_1239 SAUSA300_1224 2.05 thrA aspartate kinase 
NWMN_1241 SAUSA300_1226 2.39 hom homoserine dehydrogenase 
NWMN_1242 SAUSA300_1227 2.71 thrC threonine synthase 
NWMN_1243 SAUSA300_1228 2.89 thrB homoserine kinase 
Lys 
NWMN_1305 SAUSA300_1286 2.18 asd aspartate-semialdehyde dehydrogenase 
NWMN_1306 SAUSA300_1287 2.39 dapA dihydrodipicolinate synthase 
NWMN_1307 SAUSA300_1288 2.65 dapB dihydrodipicolinate reductase 
NWMN_1308 SAUSA300_1289 2.74 dapD 
2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-
succinyltransferase 
Val, Leu, Ile 
NWMN_1960 SAUSA300_2005 4.45 ilvD dihydroxy-acid dehydratase 
NWMN_1961 SAUSA300_2006 4.48 ilvB acetolactate synthase, large subunit, biosynthetic type 
NWMN_1963 SAUSA300_2008 4.94 ilvC ketol-acid reductoisomerase 
NWMN_1964 SAUSA300_2009 4.64 leuA 2-isopropylmalate synthase 
NWMN_1965 SAUSA300_2010 4.85 leuB 3-isopropylmalate dehydrogenase 
NWMN_1966 SAUSA300_2011 4.27 leuC 3-isopropylmalate dehydratase, large subunit 
NWMN_1967 SAUSA300_2012 3.97 leuD 3-isopropylmalate dehydratase, small subunit 
NWMN_1968 SAUSA300_2013 2.56 ilvA2 threonine dehydratase 
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Table 2 cont’d: Transcripts regulated by SaeRS under anaerobiosis and ‘882 treatment 
Newman USA300 Fold change Gene name Gene description 
Glu 
NWMN_0145 SAUSA300_0202 2.33 - peptide ABC transporter, permease protein 
NWMN_0147 SAUSA300_0204 2.29 ggt gamma-glutamyltranspeptidase; releases cysteine from glutathione
NWMN_0436 SAUSA300_0445 2.42 gltB glutamate synthase, large subunit 
NWMN_0437 SAUSA300_0446 2.72 gltD glutamate synthase, small subunit 
His 
NWMN_0692 SAUSA300_0708 2.68 hisC histidinol-phosphate aminotransferase 
Cell Envelope 
NWMN_0193 SAUSA300_0253 -2.59 scdA cell wall synthesis 
NWMN_1145 SAUSA300_1128 -2.01 - 
cell division protein FtsY, 
putative; FtsY recognizes signal 
peptide for secretion 
NWMN_1342 SAUSA300_1324 -2.92 - membrane protein, putative 
NWMN_1309 SAUSA300_1291 2.95 hipO peptidase, M20/M25/M40 family 
NWMN_1310 SAUSA300_1292 3.09 alr2 alanine racemase family protein, pyridoxal 5'phosphate dependent 
Transport 
NWMN_0856 SAUSA300_0887 2.43 oppB oligopeptide ABC transporter, permease protein 
NWMN_0857 SAUSA300_0888 2.27 oppC oligopeptide ABC transporter, permease protein 
NWMN_0858 SAUSA300_0889 2.47 oppD oligopeptide ABC transporter, ATP-binding protein 
NWMN_0859 SAUSA300_0890 2.86 oppF oligopeptide ABC transporter, ATP-binding protein 
NWMN_0860 SAUSA300_0891 2.69 oppA oligopeptide ABC transporter, oligopeptide-binding protein 
NWMN_2303 SAUSA300_2349 -2.27 - formate/nitrite transporter family protein 
NWMN_2500 SAUSA300_2538 2.32 - amino acid permease 
NWMN_2581 SAUSA300_2616 2.75 - cobalt transport family protein 
NWMN_2582 SAUSA300_2617 3.67 - ABC transporter, ATP-binding protein 
NWMN_2584 SAUSA300_2619 3.61 - conserved hypothetical protein 
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Table 2 cont’d: Transcripts regulated by SaeRS under anaerobiosis and ‘882 treatment 
Newman USA300 Fold change Gene name Gene description 
Virulence factors and exoproteins 
NWMN_0362 SAUSA300_0370 68.74 - staphylococcal enterotoxin, putative 
NWMN_0388 SAUSA300_0395 12.85 ssl1nm exotoxin 3, putative 
NWMN_0389 SAUSA300_0396 23.62 ssl2nm/set7 exotoxin 1, putative 
NWMN_0390 SAUSA300_0397 7.81 ssl3nm exotoxin 8 
NWMN_0392 SAUSA300_0399 5.48 ssl5nm exotoxin 3 
NWMN_0393 SAUSA300_0400 5.81 ssl6nm exotoxin 
NWMN_0395 SAUSA300_0402 21.35 ssl8nm exotoxin 12 
NWMN_0396 SAUSA300_0403 29.33 ssl9nm exotoxin 5, putative 
NWMN_0397 SAUSA300_0404 14.54 ssl10 exotoxin 4, putative 
NWMN_0758 SAUSA300_0774 53.71 empbp/ssp secretory extracellular matrix and plasma binding protein 
NWMN_1067 SAUSA300_1053 60.29 - 
hypothetical protein, formyl 
peptide receptor-like 1 inhibitory 
protein 
NWMN_1246 SAUSA300_1232 2.25 katA Catalase 
NWMN_1075 SAUSA300_1059 14.62 - exotoxin 1, putative 
NWMN_1076 SAUSA300_1060 22.31 - exotoxin 4, putative 
NWMN_1077 SAUSA300_1061 69.11 - exotoxin 3, putative 
NWMN_1872 SAUSA300_1917 137.5 map map protein, authentic frameshift 
NWMN_1926 SAUSA300_1973 64.33 hlb phospholipase C 
NWMN_2318 SAUSA300_2365 94.07 hlgA gamma-hemolysin, component A 
NWMN_2320 SAUSA300_2367 135.74 hlgC gamma hemolysin, component C 
NWMN_2321 SAUSA300_2368 47.03 hlgB gamma hemolysin, component B 
Hypothetical 
NWMN_0150 SAUSA300_0207 2.45 - M23/M37 peptidase domain protein 
NWMN_0206 SAUSA300_0266 -2.5 - hypothetical protein 
NWMN_0402 SAUSA300_0409 114.43 - hypothetical protein 
NWMN_0896 SAUSA300_0929 2.1 - hypothetical protein 
NWMN_2370 SAUSA300_2417 2.39 - transporter, putative 
NWMN_2579 SAUSA300_2614 2.06 - hypothetical protein 
NWMN_2608 SAUSA300_2642 -2.71 - conserved hypothetical protein 
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Discussion 
 This chemical genetics approach to understanding the mechanism of ‘882 toxicity has 
begun to reveal a source of anaerobic toxicity for S. aureus. The successful isolation of nine ‘882-
resistant strains, each strain null for SaeRS activity, has led to the conclusion that the SaeRS TCS 
is required for ‘882-induced anaerobic toxicity, but not heme biosynthesis and HssRS activation. 
Furthermore, it was noted that USA300 LAC was resistant to ‘882 toxicity, while Newman was 
sensitive. Converting Newman SaeS proline 18 to leucine, which is present in USA300 LAC 
SaeS, provided resistance to ‘882 indicating that the hyperactivity of Newman SaeS is required 
for ‘882 toxicity. Finally, it was determined that ‘882 activates SaeRS expression in Newman and 
represses SaeRS expression in USA300 LAC. It is likely that the up-regulation of SaeRS in 
Newman by ‘882 is a source of stress during anaerobic growth. 
 The toxicity of ‘882 toward other bacterial species that do not encode SaeRS points to the 
hypothesis that a cellular factor impacted by SaeRS activity is the target of ‘882. To identify 
genes differentially regulated by SaeRS, microarray analysis was performed to identify 
transcriptional changes in Newman and Newman ∆saeRS under anaerobiosis. In total, 95 coding 
transcripts, which comprise 74 unique operons, were differentially regulated by SaeRS. The next 
step is to identify if any of these genes are involved in ‘882 toxicity. To begin to assess the 
contribution of each transcriptional target in anaerobic ‘882-toxicity, the 36 genes that are not 
predicted to be toxins but are available in the NARSA transposon library are being transduced 
into Newman to determine if they contribute to sensitivity to ‘882 toxicity or anaerobic growth. 
The first seven genes tested do not contribute to ‘882 toxicity. The remaining genes will be 
analyzed in the future.  
 It is possible that the target of ‘882 is an essential gene and is therefore not present in the 
NARSA transposon library. In fact, it is quite likely, as suppressor mutations have only been 
identified in the saePQRS locus. It is possible that the loss of saePQRS titrates the target of ‘882 
to levels that still allow growth but prevent ‘882-induced toxicity. If this is the case, a strain of 
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Newman will be generated that contains two copies of the saePQRS operon. This strain can then 
be used to select for ‘882 suppressor strains. Isolating ‘882 resistance in this strain would require 
two mutations in two independent sae operons in order for the bacteria to become resistant to 
‘882, which would have a much lower frequency of occurence. This may allow other suppressor 
mutants to be isolated that have mutations distinct from the saePQRS locus. 
 The requirement of Newman SaeRS for ‘882 toxicity is intriguing. The SaeRS TCS 
positively regulates hemolysins and has been reported to be repressed upon heme exposure and 
activated upon iron limitation, thus implicating SaeRS in contributing to iron and heme 
homeostasis; these observations were made in an S. aureus strain encoding SaeS Leu18 (72). 
Despite increasing intracellular levels of heme, ‘882 actually increases Newman SaeRS activity. 
As expected, ‘882 does repress SaeRS activity in USA300, which encodes SaeS Leu18. It is 
possible that the hyperactivity of the SaeS Pro18 encoded by Newman may override heme-
induced repression of SaeRS signaling. It could be this inappropriate regulation of SaeRS in 
response to endogenous heme levels that results in ‘882 toxicity. Nonetheless, the inappropriate 
response of SaeRS to endogenous heme levels is unlikely to be the source of ‘882 toxicity as 
heme biosynthesis is not required for ‘882 toxicity (Figure 4B). That is, ‘882 is still toxic to 
anaerobic S. aureus without activating endogenous heme biosynthesis. These data suggest that it 
is neither heme nor the regulation of SaeRS by heme that is the source of ‘882 toxicity. 
Nonetheless, HssRS and SaeRS are two heme responsive TCSs in S. aureus. HssRS 
seems to solely sense heme while SaeRS activity is also impacted by human neutrophil peptides, 
oxygen, and iron. It is possible that SaeRS and HssRS may have a complex signaling network 
that integrates information on the nutrient status of the cell and the external environment to 
coordinate the metabolic and virulence programs of the bacteria with these signals. Perhaps ‘882 
twitches a thread in this complex web of energy homeostasis to exert its effects on heme 
biosynthesis and anaerobic growth.  
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 Further work towards identifying the source of ‘882-induced anaerobic toxicity is critical. 
To further confirm that it is the hyperactivity of SaeS Pro18 that generates ‘882 toxicity, the 
Newman SaeRS has been cloned into the ∆saePQRS USA300 genome (5). This strain provides 
the opportunity to investigate the sufficiency of the Newman SaePQRS in conferring ‘882 
sensitivity to USA300 LAC. Pinpointing the source of ‘882 toxicity in S. aureus may identify 
pathways that, when manipulated appropriately, limit S. aureus fermentative growth. Specifically 
targeting fermentative growth does have utility as there are circumstances in which S. aureus 
relies on fermentation to resist host defenses, antibiotics and successfully colonize its host 
(Chapter III). Therefore, identifying this ‘Achilles heel’ of S. aureus fermentation will allow for 
future work to improve ‘882 activity and develop new methods for targeting anaerobic growth. 
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CHAPTER V 
 
PROBING A BACILLUS ANTHRACIS SIGNALING NETWORK WITH VU0120205 
 
Introduction 
 Two-component signaling systems (TCSs) are the primary way bacteria sense and adapt 
to changes in their environment. TCSs are present in nearly all sequenced bacterial genomes; 
most species encode 20-30 TCSs, while others carry upwards of 200-300 putative TCSs (78). The 
classic bacterial TCS system is thought to function in a linear fashion, in that each HK has a 
defined input and that results in a specific output from the RR. The appreciation that interactions, 
both beneficial and detrimental, occur between TCSs has become more prevalent. This ‘cross-
talk’ has been previously defined as the “communication between two pathways that, if 
eliminated, would leave intact two distinct, functioning pathways” (41). When cross-talk between 
two signaling systems benefits an organism this is referred to as ‘cross-regulation’ (41). 
 Bacillus anthracis is predicted to encode approximately 45 TCSs. In B. anthracis, all 
HKs and RRs share at least 20% identity with other encoded HKs and RRs. This conservation is 
manifested primarily in the domains involved in the phosphotransfer event of the signaling 
pathway. It is the input domains of HKs and the output domains of RRs that are more variable. 
This allows TCSs to sense a variety of environmental signals to enact an array of outputs, while 
the fundamental mechanisms of HK autophosphorylation and phosphotransfer to the RR remain 
central to the function of the system. The mechanisms by which a single HK maintains fidelity to 
its cognate RR in a bacterial cell expressing 20-300 other HK-RR pairs is a major question in 
TCS research. 
 The current understanding of how HK-RR signaling purity is maintained implicates 
molecular recognition, HK phosphatase activity, and substrate competition as the primary 
mechanisms for ensuring specificity (62). That is to say molecular recognition dictates that each 
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HK-RR pair has co-evolved amino acid residues that drive a strong preference for 
phosphotransfer from the HK to its cognate RR. This phenomenon is observable in vitro as most 
HKs have a strong kinetic preference for their cognate RR over other RRs encoded in the same 
genome (79). Furthermore, if a HK is a bi-functional kinase/phosphatase, its phosphatase activity 
is specific for its cognate RR (28). This buffers against non-specific phosphorylation of the 
cognate RR and limits the activation of the pathway (62). Specificity is further maintained by a 
high ratio of RR:HK, which would essentially allow the cognate RR to outcompete other RRs for 
binding to its cognate HK (8, 62). Specificity may also be influenced by the temporal expression 
and spatial localization of TCSs (41).  
 Much focus has been on the maintenance of specificity at the HK-RR level and the 
general conclusions have been that cross-talk between non-cognate HK-RR pairs is possible, but 
atypical. It may be more likely for cross-talk to occur at other points in the signal transduction 
pathway. At the transcriptional level, multiple RRs may influence overlapping sets of genes (41). 
Alternatively, a protein product regulated by a RR may itself be a transcriptional regulator or 
phosphatase that impinges on the regulatory outputs of other TCSs (41). Essentially it has become 
clear that bacterial signaling networks are not purely insulated linear systems that have a singular 
response to a particular input. Rather the complex interactions of TCSs at both the HK-RR and 
post-RR regulatory levels allow bacteria to integrate multiple signals to generate the appropriate 
biological response. 
 Bacillus anthracis is an environmental pathogen that inhabits various environments 
ranging from the soil to a myriad of mammalians hosts. To survive and persist in adverse 
environments, B. anthracis also possesses the ability to sporulate. Sporulation is a complex 
process regulated by a complex TCS-like phosphorelay system. During B. subtilis sporulation, at 
least five different HKs impinge upon a single response regulator (86). The complex 
phosphorelay pathways employed by the Bacilli during sporulation hint at the possibility that this 
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genus may be particularly adept at integrating environmental signals to initiate an appropriate 
response as well as insulating against unwanted cross-talk between signaling systems.   
 To further study the activation of the HssRS TCS, the activity of the S. aureus HssRS 
activators were screened for activation of the hrt promoter (phrt) in B. anthracis. Since B. 
anthracis is closely related to S. aureus, it was hypothesized that small molecule activators of S. 
aureus HssRS may also activate B. anthracis HssRS. The top 14 hits from the HTS were assessed 
for XylE activity in B. anthracis, and some were found to increase phrt activity. Compound 
VU0120205 (‘205) became of particular interest as it activates phrt independent of HssRS. This 
resulted in the identification of a second TCS that cross-talks with HssRS. The new HK is called 
BAS1817 and its cognate RR is BAS1816. Data presented in this chapter characterize BAS1816-
17 as a TCS and dissect the bi-directional mechanisms by which HssRS and BAS1816-17 
influence each other. Finally, in an effort to understand the native function of BAS1816-17 other 
small molecule activators of this TCS are identified. In summary, this chapter uses chemical 
biology to probe a new B. anthracis signal transduction network to understand the integration of 
heme homeostasis with other environmental signals.  
 
Methods 
Bacterial strains and growth conditions – B. anthracis strain Sterne was used for all experiments 
(87). It was grown in BHI or LB. All plasmid construction was performed in E. coli DH5α or 
TOP10. To move plasmids from E. coli to B. anthracis they were first transformed into E. coli 
K1077 (37). Proteins were expressed in E. coli BL21DE3 pREL. Antibiotic concentrations used 
were ampicillin 100 μg/ml in E. coli (pET15b constructs), chloramphenicol 10 μg/ml in B. 
anthracis (XylE reporter assays) and 34 μg/ml in E. coli (protein expression) and kanamycin 20 
μg/ml in B. anthracis and 40 μg/ml in E. coli (knockout generation). 
Preparation of heme and other compound stocks – 10 mM heme stocks (Fluka) were prepared 
daily in 0.1 M NaOH. A 50 mM stock of ‘205 was prepared in DMSO and stored at -20°C. A 20 
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mM stock of NDGA was prepared in ethanol and stored at -20°C. Stocks of 250 μM vancomycin 
and 100 mM chlorpromazine were prepared in water and stored at -20°C. A 1 M stock of sodium 
phosphate monobasic was prepared in water, brought to a pH of 7, and stored at room 
temperature. A stock of 20 mg/ml of targocil was prepared in DMSO and stored in the dark at 
4°C. 
Genetic manipulation of B. anthracis – Electroporations and mutant generation were performed 
as previously described (83). Electroporations were also performed with the following 
modifications. DNA purified for K1077 E. coli was eluted in 10 mM Tris-HCl, pH 8.5 and this 
solution was used for electroporations. After the B. anthracis competent cells were prepared, the 
optical density at 600 nm (OD600) was determined in phosphate buffered saline (PBS, 137 mM 
NaCl, 2.7 mM KCl, Na2HPO4 10 mM, KH2PO4 1.8 mM, pH 7.4). Cells were flash frozen in 
liquid nitrogen and thawed on ice for electroporations. For electroporation the competent cells 
were diluted in SMG (0.5 M D-sorbitol, 0.5 M D-mannitol, 10% glycerol) to a final OD600 of 8.0. 
To 50 μl of cells 0.5 – 5 μl of DNA was added (approximately 3 μg total). Cells were incubated 
with DNA in a pre-chilled 1 mM cuvette for 1 minute on ice and then electroporated using the 
conditions described previously (83). Cells were recovered in 1 ml BHI + 0.5 M D-sorbitol for 3 
h at 30°C, 200 rpm in aeration tubes. All knockouts were generated without an antibiotic cassette. 
Instead, 1,000 bp (including 100 bp of the target gene) from the 5’ and 3’ flanking regions of the 
gene targeted for deletion were cloned into the pLM4 knockout vector to generate clean 
knockouts.  
Generation of xylE reporter plasmids – The BAS1814 promoter xylE reporter construct was 
generated in a pOS1 background (74). The BAS1814 promoter-xylE fusions was generated by 
PCR-SOE (31) . This resulted in a seemless fusion between the BAS1814 promoter and the xylE 
reporter gene. PCR-SOE DNA was digested with BamHI and EcoRI and ligated into pOS1. 
Mutagenesis of the BAS1814 DR was carried out by inverse PCR-based mutagenesis. The 
selected mutations were incorporated on one primer and a second non-overlapping, non-
77 
 
mutagenic primer was designed to amplify in the opposite direction. The primers were 5’ 
phosphorylated by T4 polynucleotide kinase (NEB) and the parental plasmid amplified using the 
high-fidely DNA polymerase Pfu Turbo. The amplified DNA was blunt end ligated and 
transformed into E. coli. Mutagenized constructs were verified by DNA sequencing.   
XylE assays – XylE assays were performed as described previously with the following exceptions 
(83). All cultures were grown overnight in 5 ml LB/chloramphenicol at 30°C, 180 rpm. Bacteria 
were sub-cultured into 4 ml LB/chloramphenicol and grown as indicated: either 1:100 sub-culture 
and growth for 6 h at 37°C, 180 rpm or 1:1,000 sub-culture and growth for 24 h at 37°C, 180 
rpm. 
Generation of protein purification constructs – BAS1816 was amplified from genomic DNA by 
Pfu Turbo using the 3rd ATG as the start site. Inverse PCR was used to insert a SacII site in the 
multiple cloning site (MCS). Briefly, two complementary, overlapping primers that amplify in the 
opposite direction were designed, which included the addition of the SacII site after the BamHI 
restriction. The PCR product was transformed into E. coli and successful incorporation of the 
SacII site was confirmed by sequencing. This inverse PCR generated pLOLA (pET15b.SacII) and 
resulted in the MCS changing from: CATATGCTCGAGGATCCGGCTGCT to 
CATATGCTCGAGGATCCGGCCGCGGCTGCT. The BAS1816 PCR product was digested 
with SacII and BamHI-HF (NEB) and ligated into pLOLA.  The intracellular domain (ICD) (bp 
221 to the end) of BAS1817 was amplified using Pfu Turbo and digested with SmaI. The vector 
pET15b was digested with XhoI and purified using the Qiagen gel purification kit. Blunt ends 
were generated on pET15b by treating the cut vector with DNA Polymerase I, Klenow fragment 
(NEB). The Klenow fragment was inactivated, the vector was column purified and blunt-end 
ligated to the digested BAS1817 ICD. The mutation of BAS1816 D56N and BAS1817 ICD 
H137A were generated by inverse PCR as described above. All constructs result in the generation 
of N-terminal hexahistidine-tagged proteins and were transformed into BL21 DE3 pREL. 
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Protein purification – Protein purifications were carried out as described previously with the 
following modifications (82). All proteins were induced in 0.5 mM IPTG, cells were lysed for 5 
min on an EmulsiFlex C3 (Avestin) at a peak PSI of 20,000 and the lysates were centrifuged at 
20,000 x g for 1 h at 4°C. BAS1817 ICD and HssR ICD and their corresponding mutants were 
purified in TSB containing 10 mM imidazole and eluted in 75 mM imidazole in TBS. BAS1816 
and HssR and their corresponding mutants were purified in TSB containing 1 mM EDTA, 10% 
glycerol, and 10 mM imidazole and eluted in 50 mM imidazole in TBS. BAS1816 was induced 
after 2 h of growth at 16°C in 0.5 mM IPTG and a second time 5 h later with an equal volume of 
IPTG to bring the final concentration to 1 mM.  
Autophosphorylation and phosphotransfer assays – Autophosphorylation assays were performed 
as described previously with the following modifications (83). Ten μl autophosphorylation 
reactions were assembled with HssS and BAS1817 ICDs and their corresponding mutatnts were 
used at a final concentration of 5 μM (640 μg/ml). For HssS 10 μCi of [γ-32P]-ATP was used and 
due to the high autophosphorylation of BAS1817, 5 μCi of [γ-32P]-ATP was used. All reactions 
were incubated at 37°C for 30 min. To analyze the phosphotransfer of each HK to each RR, the 
HKs were autophosphorylated as described above in a 30 μl reaction volume. After the HKs 
autophosphorylated for 30 min, 10 μl were sampled into 2X SDS-PAGE loading buffer. To the 
remaining 20 μl, 3 μl of 100 μM RR was added for a final concentration of approximately 10 μM. 
HK-RR mixtures were incubated for 5 min and then 10 μl was sampled into 2X SDS-PAGE 
loading buffer. Samples were analyzed as described previously (83). To examine the preferential 
phosphotransfer of each HK for each RR, a 220 μl autophosphorylation reaction was run for each 
HK. Serial dilutions of each RR were prepared so that when 2 μl of the RR stock was added to 
9.5 μl of phosphorylated HK, the final RR concentration was 20, 10, 5, 2.5, 1.25, 0.625, 0.31, 
0.16, 0.08, and 0.04 μM. Each RR concentration was incubated with each phosphorylated HK for 
30 sec, after which 10 μl of 2X SDS-PAGE buffer was added. The samples were stored on ice 
and analyzed as described previously (83). 
79 
 
Biolog Phenotypic Microarray Screen – Phenotypic Microarray plates (PM 1-20) and IF-0a 
GN/GP (1.2X) were purchased from Biolog. Preparation of PM inoculating fluids was adapted 
from the manufacturer’s recommendations for B. subtilis. The following solutions were prepared: 
PM-A = 800 mM tricarballylic acid, pH 7.1; PM-B = 240 mM MgCl2 and 120 mM CaCl2; PM-C 
= 3 mM L-arginine and 6 mM L-glutamic acid; PM-D = 0.5 mM L-cystine pH 8.5 and 1 mM 5’-
UMP; PM-E = 0.6% yeast extract; PM-F = 0.6% tween-80; PM-G = 300 mM D-glucose and 600 
mM pyruvate. In all instances pH was adjusted with NaOH and all solutions were filter sterilized 
and stored at 4°C. 12X PM additive for PM-1,2 = 5 ml each of PM-B, PM-C, PM-E, PM-F, and 
15 ml each of PM-D and sterile water.  12X PM additive for PM-3,6,7 = 5 ml each of PM-B, PM-
E, PM-F, PM-G and 15 ml each of PM-A and PM-D.  12X PM additive for PM-4 = 5 ml each of 
PM-B, PM-C, PM-E, PM-F, PM-G and 15 ml of PM-A and 10 ml of sterile water. 12X PM 
additive for PM-5 = 5 ml each of PM-B and PM-G and 15 ml of PM-A and 25 ml of sterile water. 
12X PM additive for PM-9-20 = 5 ml each of PM-B, PM-E, PM-F, PM-G and 30 ml of sterile 
water. The inoculating solution for each plate consisted of 20 ml of IF-0A GN/GP (1.2X), 2 ml of 
12X PM additive (specific for each plate, described above), and 20 μl of 10 mg/ml 
chloramphenicol. B. anthracis p14.xylE was grown overnight on solid media and the colonies 
were inoculated into the inoculating solution to a final OD600 of approximately 0.6. The 
inoculating solution with the bacterial suspension was aliquoted 100 μl into each well of a 96 well 
PM plate. A single well was also inoculated with 1.67 μl of 50 mM ‘205 as a positive control; the 
well was selected based on chemical redundancy with other wells on the same plate to avoid 
masking a potential hit. Plates were covered with a Kim wipe to allow oxygen exchange and 
incubated at 37°C, 180 rpm. At 3 h and 5 h, wells with significant liquid loss were supplemented 
with 50 μl of sterile water. After 6-7 h, each PM plate was centrifuged at 3,200 x g for 10 min. 
The supernatant was removed by pipetting and the plate frozen at -80°C. To analyze the XylE 
activity, the PM plates were thawed and cells were lysed by the addition of 50 μl of 2 mg/ml 
lysozyme in 100 mM potassium phosphate buffer (pH 8.0), 10% (v/v) acetone. Cells were 
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incubated at 37°C for 30 min. To each well 25 μl of 100 mM potassium phosphate (pH 8.0), 0.2 
mM pyrocatechol was added immediately before assaying XylE activity (85). Each PM plate was 
screened twice, using a different well for a ‘205 positive control each time. 
 
Results 
Compound VU0120205 (‘205) activates the phrt direct repeat independent of HssR. 
Compound ‘205 was evaluated for HssRS activation in B. anthracis by quantifying the activation 
of the hrt promoter fused to the xylE reporter gene (phrt.xylE). This compound has negligible 
activation of phrt in wildtype B. anthracis; although, some activation could be masked by the 
high basal phrt expression in B. anthracis (Figure 19A and B) (83). What is most notable about 
this compound is that the phrt promoter was still activated upon ‘205 exposure by nearly 100-
fold, while all activation of phrt by heme was absent in ΔhssR (Figure 19A). The activation of 
phrt by ‘205 was ablated when the four nucleotides required for HssR recognition in the direct 
repeat (DR) of the hrt promoter were mutated (Figure 19). These data suggest that there is at least 
one other regulator in B. anthracis that stimulates hrt expression through the hrt DR and that this 
regulator is activated by ‘205. This hypothesis is supported by the observation that there is a 
second DR in B. anthracis that is closely related to the DR in phrt (12).  
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Figure 19. ‘205 activates the B. anthracis hrt promoter through two pathways that depend 
on the direct repeat. A. Wildtype (wt) and ΔhssR B. anthracis Sterne were transformed with the 
hrt promoter fused to the xylE reporter gene (phrt.xylE). The direct repeat (DR) of the hrt 
promoter-xylE fusion was mutated (phrtDR.xylE) and transformed into wt. Each strain was grown 
in triplicate in the presence of either vehicle (DMSO), 1 µM heme, or 50 µM ‘205 for 24 h. XylE 
activity in cell lysates was quantified. Shown are data representative of at least three replicates. 
Error bars represent one standard deviation from the mean. B. Structure of VU0120205 C. 
Genomic locus (top) and DR (bottom) of BAS1814-17. In the inset is an alignment of the direct 
repeats found in the hrt promoter (phrt) regions of S. aureus and B. anthracis and the BAS1814 
promoter (p14) region in B. anthracis. Highlighted in bold are nucleotides previously shown to be 
required for HssR recognition of the phrt DR (83). Underlined in red are nucleotides that differ 
between p14 and phrt. Superscript numbers indicate the nucleotide distance from the start site. 
Each DR remains 18 base pairs from the predicted ribosome binding site. 
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 This alternative DR retains the four nucleotides required for HssR binding, but differs 
from phrt by four other nucleotides (Figure 19C) (83). This previously uncharacterized DR is 
located in the promoter region (p14) of the BAS1814-17 operon. BAS1814 and BAS1815 are 
conserved in the Bacilli genus and are predicted to function together as an ABC transporter. 
BAS1816 and BAS1817 are a putative TCS in B. anthracis where BAS1817 is the histidine 
kinase (HK) and BAS1816 is the response regulator (RR) that is predicted to regulate p14 (12). 
Furthermore, protein BLAST analysis of BAS1816 in B. anthracis identifies HssR as the most 
similar RR in B. anthracis with 87% coverage and 52.5% identity. A similar analysis of 
BAS1817 identifies HssS as the most similar HK in B. anthracis with 81.8% coverage and 40.7% 
identity. It is intriguing that HssRS is most closely related to the BAS1816-17 TCS in B. 
anthracis and that they share a very similar DR. These observations lead to the hypothesis that 
BAS1816-17 is a functional TCS that responds to ‘205 and regulates both p14 and phrt. 
 
Compound ‘205 activation of p14 and phrt is mediated through BAS1816-17. To determine if 
BAS1816 and BAS1817 auto-regulate the BAS1814-17 operon in response to ‘205 treatment, the 
BAS1814 promoter was fused to the xylE reporter gene (p14.xylE) and transformed in wildtype, 
ΔhssRS, ΔBAS1816-17, and ΔhssRS/BAS1816-17. These strains were grown in the presence of 
vehicle (DMSO) or 50 µM ‘205 and then XylE activity was quantified. The BAS1814 promoter 
(p14) is activated in the presence of ‘205 in a manner that requires BAS1816-17, not HssRS 
(Figure 20A). The four nucleotides in the p14 DR, which are shown in bold in Figure 19C and 
were previously determined to be required for HssR activation of the hrt promoter were mutated 
on the p14.xylE reporter plasmid and transformed into wildtype B. anthracis. Mutation of these 
four nucleotides ablated ‘205 activation of p14 (Figure 20A). Together these data reveal that ‘205 
activates BAS1816-17, which auto-regulates the p14 DR through four conserved nucleotides. 
These experiments were repeated using 2 µM heme as the activating compound instead of ‘205. 
Heme does not activate p14 at this concentration (Figure 20B).  
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 In Figure 19A it was observed that ‘205 activates phrt independently of HssR but 
requiring the phrt DR. To determine if this activation of the hrt promoter was due to BAS1816-17 
activity, the phrt.xylE reporter plasmid was transformed into ΔBAS1816-17 and 
ΔhssRS/BAS1816-17. The high basal activation of phrt masked any ‘205-induced activation of 
this promoter in ΔBAS1816-17; however, the ‘205-induced activation of phrt in ΔhssRS was 
ablated in the quadruple ΔhssRS/BAS1816-17 knock-out (Figure 20C). These data reveal that the 
‘205-induced activation of phrt is indeed mediated through BAS1816-17. 
 B. anthracis HssRS has already been well-characterized to activate phrt in response to 
heme treatment. To determine if BAS1816-17 responds to heme and regulates the hrt promoter, 
the activation of phrt in ΔBAS1816-17 upon treatment with 1 μM heme was quantified and found 
to be similar to wildtype (Figure 20D). This indicates that BAS1816-17 does not activate the hrt 
promoter in response to heme. 
 In summary these experiments identify BAS1816-17 as a new TCS that is activated by 
compound ‘205. BAS1816-17 can activate both the phrt and p14 promoters. Reciprocally, HssRS 
is activated by heme and regulates phrt (83). At the concentrations used in these experiments 
neither p14 nor BAS1816-17 were responsive to heme. These two TCSs present a unique 
opportunity to study the mechanisms by which similar TCSs either integrate or maintain their 
signaling purity and may provide insight into how bacteria adapt to diverse environmental 
signals. Due to the similarity of the DRs and RRs of BAS1816-17 and HssRS, it is possible that 
an activated RR may be able to act at both DRs. Alternatively, cross-signaling may occur due to 
phosphorylation of a non-cognate RR by a HK. The role of RR-DR and HK-RR interactions in 
maintaining signaling purity will be investigated in subsequent data sections. 
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Figure 20. BAS1816-17 activates both the BAS1814 and hrt promoters while HssRS 
activates just the hrt promoter. Wildtype (wt), ΔhssRS, ΔBAS16-17 (Δ16-17), ΔhssRS/Δ16-17 
were transformed with the BAS1814 promoter fused to the xylE reporter gene (p14) (A and B) and 
hrt promoter fused to the xylE reporter gene (phrt) (C and D). Wt was also transformed with a 
promoterless xylE (pOS1) and the direct repeat of each promoter mutated (p14DR and phrtDR). 
Each strain was grown in triplicate and exposed to either vehicle (DMSO) or 50 µM ‘0070 (A and 
C), or 2 µM heme (B and D) for 24 h. Cells were lysed and XylE activity was quantified. Shown 
are data averaged from at least two independent experiments performed with biological 
triplicates. Error bars represent one standard deviation from the mean. XylE assays were 
performed by LQO. 
  
85 
 
The direct repeat determines the response of each promoter region. The four nucleotides of 
the phrt DR previously shown to be required for HssR-phrt DR interactions are conserved in the 
p14 DR. However, four other nucleotides of the DR discriminate the phrt DR from the p14 DR. 
This leads to the hypothesis that the four nucleotides unique to p14 are sufficient to differentially 
regulate p14 as compared to phrt. To test this hypothesis, the four nucleotides unique to the p14 
DR were incorporated into the phrt.xylE reporter construct to make phrt.14DR.xylE and the four 
nucleotides unique to the phrt DR were switched into the p14.xylE reporter construct to generate 
p14.hrtDR.xylE. These constructs were transformed into wildtype B. anthracis and then the 
strains were exposed to either heme or ‘205. The response of each promoter to heme and ‘205 
was quantified by measuring the XylE activity in each strain.  
 As predicted, swapping the four unique nucleotides in each DR switches the 
responsiveness of each promoter to heme and ‘205 (Figure 21). Therefore these four unique 
nucleotides in the p14 DR are sufficient to determine the response of the promoter to 
environmental stimuli. One exception to this result is the loss of the high basal activation of phrt 
when the phrt DR was placed in p14. This result, when considered in conjunction with previous 
observations that the high phrt background is also lost upon hssR deletion and phrt DR mutation 
(Figure 19A and 20C-D), suggests that the high basal activation of phrt is due to the interaction of 
HssR with the phrt DR in the context of phrt.  
It is important to note that since only wildtype B. anthracis was investigated in this 
experiment, the bacteria could be treated with a higher concentration of heme (5 µM). This 
concentration of heme activates p14 and phrt.14DR in wildtype B. anthracis. Since this strain has 
all TCSs intact the activation of p14 by heme suggests that cross-talk from HssRS to BAS1816-
17 does occur naturally. 
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Figure 21. The direct repeat in each promoter determines specificity in vivo. Wildtype B. 
anthracis Sterne was transformed with the hrt promoter fused to the xylE reporter gene (phrt) and 
the BAS1814 promoter fused to the xylE reporter gene (p14). Furthermore, the direct repeat of 
each promoter was swapped into the other reporter plasmid (phrt.14DR and p14.hrtDR) and 
transformed into wildtype B. anthracis. Each strain was grown in triplicate and exposed to either 
vehicle (DMSO), 5 µM heme, or 50 µM ‘0070 for 24 h. Cells were lysed and XylE activity was 
quantified. Data are averaged from at least 4 independent experiments. Error bars represent one 
standard deviation from the mean. Plasmids were generated by DLS. 
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Cross-talk at the response regulator-direct repeat level is limited. It is remarkable that four 
nucleotides allow for discrete regulation of two very similar DRs. Swapping the DRs between 
promoter regions, however, does not indicate whether each RR influences its cognate DR 
exclusively. To investigate if a RR impacts the recognition of its non-cognate DR, each RR was 
individually mutated and then promoter activation was analyzed in the mutant strains. 
 First the influence of BAS1816 on the phrt DR was examined. The phrt.xylE and 
p14.hrtDR.xylE reporter constructs were transformed into wildtype, ΔhssR, and ΔhssR/1816 
strains. BAS1816-17 was stimulated with 50 µM ‘205 and the vehicle DMSO was used as a 
negative control, see Figure 22A for a scheme of the experimental design. As expected, activation 
of phrt was observed upon deletion of ΔhssR and was lost in ΔhssR/1816 (Figure 22C). The 
elimination of the high basal activity of phrt in p14.hrtDR revealed low levels of phrt DR 
recognition in wildtype in addition to ΔhssR; nearly all activation was lost in ΔhssR/1816 (Figure 
22C). These data utilizing both reporter constructs suggest that BAS1816 can recognize the phrt 
DR; however, the high basal activity of wildtype phrt may limit BAS1816 influence on its non-
cognate DR under native conditions. 
 Next the ability of HssR to regulate p14 was probed. Using an analogous strategy, the 
p14.xylE and phrt.14DR.xylE reporter constructs were transformed into wildtype, Δ1816, and 
ΔhssR/1816. HssRS was stimulated with 1 µM heme and the vehicle 0.1 M NaOH was used as a 
negative control, see Figure 22B for a scheme of the experimental design. Although there is only 
weak activation of the p14 in wildtype B. anthracis, more robust p14 activation has been 
observed in wildtype B. anthracis treated with 5 µM heme (Figure 21 and 22D). The weak 
activation of p14.xylE in wildtype is lost upon deletion of BAS1816 and unchanged in 
ΔhssR/1816 (n.b. the decrease in XylE activity in this strain upon heme treatment is most likely 
due to the heme sensitivity of ∆hssR) (Figure 22D). When the p14 DR is placed in the context of 
phrt, clear activation of phrt.14DR is observed in ΔBAS1816 and lost in ΔhssR/1816. This 
suggests that HssR may be able to recognize the p14 DR, however, it requires some other factor 
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only found on phrt. This could be either a cis-acting DNA sequence or trans-acting enhancer 
element. 
 In summary, these studies investigating the RR-DR interactions between two closely 
related TCSs suggest that BAS1816 may recognize both DRs, but other cellular factors may 
insulate this cross-talk at the RR-DR level. For example BAS1816 can recognize the phrt DR 
only in the absence of HssR or when the DR is placed in the context of p14 (Figure 22A). This 
suggests that when the phrt DR is in the context of phrt, both the presence of HssR and the 
increased activity of HssR at the phrt DR limits cross-talk from BAS1816. Conversely, p14 in 
wildtype B. anthracis is activated only at higher concentrations of heme (Figure 21). At non-toxic 
concentrations of heme, HssR does not seem to recognize the p14 DR unless it is in the context of 
phrt (Figure 22B), suggesting that other cis- or trans-acting factors enhance HssR activity 
specifically at phrt and therefore limit HssR activation of the p14 DR. These observations suggest 
that activation of p14 at higher heme concentrations may be beneficial to the bacteria. It is 
possible that the putative ABC transporter BAS1814-15 may contribute to heme tolerance in B. 
anthracis. 
 
BAS1816-17 is a two-component system that cross-phosphorylates with HssRS. To begin to 
explore the HK-RR interactions and to demonstrate that BAS1816-17 is a novel, functional TCS, 
the intracellular domain of BAS1817 and the full length BAS1816 were each N-terminally tagged 
with a hexa-histidine sequence, heterologously expressed in E. coli and purified over a Ni-NTA 
column. The full length BAS1816 as predicted based on the sequence annotated in the Sterne 
genome is highly insoluble when expressed. Within the first 81 nucleotides there are three 
predicted ATG translation start sites. When BAS1816 was aligned with homologs from other 
Bacilli it became apparent that the third ATG is most likely the true transcription start site. 
Expressing BAS1816 with the N-terminus beginning at the third predicted translation start site 
and therefore lacking the first predicted 26 amino acids resulted in pure, soluble RR.  
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Figure 22. Cross-signaling at the response regulator-direct repeat level. A. and B. Shown are 
schema of the experimental design in panels C. and D., respectively. C. Wildtype (WT) B. 
anthracis, ΔhssR, and ΔhssR/Δ1816 were transformed with the hrt promoter fused to the xylE 
reporter gene (phrt.xylE) and the hrt DR swapped into the BAS1814 promoter (p14.hrtDR.xylE). 
The six strains were each treated with either 50 µM ‘205 or an equivalent volume of the vehicle 
DMSO. Cultures were grown for 24 h and harvested. Cells were lysed and XylE activity was 
quantified. D. Wildtype (WT) B. anthracis, Δ1816, and ΔhssR/Δ1816 were transformed with the 
BAS1814 promoter fused to the xylE reporter gene (p14.xylE) and the BAS1814 DR swapped into 
the hrt promoter (phrt.14DR.xylE). The six strains were each treated with either 1 µM heme or an 
equivalent volume of the vehicle 0.1 M NaOH. Cultures were grown for 24 h and harvested. Cells 
were lysed and XylE activity was quantified. In all instances, data are averaged from at least two 
independent experiments performed with biological triplicates. Error bars represent the standard 
error of the mean. Strains were generated by DLS.  
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The conserved residues predicted to be required for phosphorelay were identified in 
BAS1816 and BAS1817 using the NCBI protein viewer. The conserved aspartate at amino acid 
position 56 in the receiver domain of BAS1816 was mutated to an asparagine and the conserved 
histidine at amino acid position 137 in the DHp domain of BAS1817 was mutated to an alanine 
(Figure 23A and B). The analogous HssS and HssR wildtype and phosphorelay-deficient proteins 
were also purified as described previously (Figure 23A and B) (83). 
First the ability of each histidine kinase to autophosphorylate was determined by 
incubating the purified HKs in the presence of γ-32P labeled ATP and then resolving the proteins 
on an SDS-PAGE gel. Each HK was autophosphorylated in the presence of ATP and these 
activities required the conserved phosphate-accepting histidines (Figure 23C). 
Next the ability of each HK to transfer the phosphate to each RR was investigated. The 
HKs were first autophosphorylated and then co-incubated with each RR for 5 min. The 
phosphorylation state of each protein was visualized by resolving each HK-RR pair on an SDS-
PAGE gel and exposing the samples to a phosphorscreen (Figure 23D). The percent of 
phosphotransfer from each HK to each RR was quantified (Figure 23E). Each HK preferentially 
phosphorylates its cognate RR, although there is significant cross-phosphorylation to each non-
cognate RR. It does not seem that HssS and BAS1817 are generally capable of phosphorylating 
any RR as the E. coli QseB RR is unable to be phosphorylated by either HK (data not shown). 
This suggests that it may be the similarity between HssR and BAS1816 that may permit cross-
phosphorylation by the HKs. 
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Figure 23. BAS1816-17 and HssRS are two-component systems that cross-phosphorylate. 
Each HK (A) and RR (B) was expressed in E. coli and purified by Ni-affinity purification. The 
dialyzed elutions were run on an SDS-PAGE gel to assess purity. C. Autophosphorylation of the 
histidine kinases and the corresponding histidine mutants. Each protein was incubated with ATP 
[γ-32P] for 30 minutes, sampled for SDS-PAGE analysis (top) and quantified by phosphorimager 
analysis (bottom). Shown is the average of four replicates and the error bars represent the 
standard deviation. (D and E) Each histidine kinase phosphorylates each response regulator. 
Histidine kinases were autophosphorylated as described in C and then co-incubated with the 
indicated response regulator for 5 minutes, sampled for SDS-PAGE analysis in D, and quantified 
by phosphorimager analysis in E. Shown in E is the average of three replicates and the error bars 
represent one standard deviation from the mean. These experiments were performed by DLS and 
JC.  
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The hierarchy of HssS and BAS1817 phosphotransfer to each response regulator. To further 
delineate the relative preference each HK has for each RR, the concentration of each RR was 
diluted over a concentration range of 2-logs. Each RR concentration was then incubated with 
auto-phosphorylated HssS or BAS1817 for 30 sec and then resolved on an SDS-PAGE gel 
(Figure 24A). The percent of phosphotransfer was quantified by dividing the intensity of the 
P~RR band over the intensity of the total density in each lane. Plotting the percent of 
phosphotransfer against the RR concentration identifies a clear hierchary in the preference for 
phosphorelay in vitro, such that the phosphotransfer of BAS1817 to BAS1816 is most efficient, 
followed by HssS to HssR, then BAS1817 to HssR, and finally HssS to BAS1816 (Figure 24B). 
The question now remains if any cross-phosphorylation occurs in vivo and if so, if the cross-
phosphorylation events have a biological function in the adaptation of B. anthracis to 
environmental changes. 
 
Selective cross-talk at the histidine kinase-response regulator level in vivo. Since cross-
phosphorylation between each HK to each RR is observed in vitro, the presence of HK-RR cross-
signaling in vivo was next investigated. To study the influence of BAS1817 phosphorylation on 
HssR activity in vivo, an ΔhssS/Δ1816 double knock-out strain was generated to eliminate any 
influence HssS or BAS1816 may have on HssR or BAS1817 (Figure 25A). This ΔhssS/Δ1816 
double knock-out strain was transformed with phrt.xylE and p14.hrtDR.xylE, which has the phrt 
DR inserted in p14. If phosphotransfer from BAS1817 to HssR occurs in vivo, then activation of 
phrt.xylE is predicted to be observed in ΔhssS/Δ1816 upon ‘205 treatment (Figure 25A). This is 
not the case (Figure 25C). When BAS1817 is stimulated by compound ‘205 phrt is not activated 
in ΔhssS/Δ1816, which indicates that despite observing strong phosphotransfer from BAS1817 to 
HssR in vitro, BAS1817 to HssR phosphorelay does not occur in vivo (Figure 25C). The 
mechanism for maintaining this signaling purity in the absence of HssS and BAS1816 remains 
unclear.  
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Figure 24. Each histidine kinase preferentially phosphorylates its cognate response 
regulator in vitro. A serial dilution of response regulator concentrations ranging from 20 µM to 
39 nM was prepared. Each histidine kinase was autophosphorylated as described earlier and then 
mixed with each response regulator concentration for 30 sec. Phosphotransfer reactions were 
quenched with SDS-PAGE loading buffer and resolved on a gel. A representative image is shown 
in A. Data from at least 4 replicates were average and plotted in B. Error bars represent one 
standard deviation from the mean. Experiments were performed by DLS and JC.  
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Figure 25. Cross-signaling at the histidine kinase-response regulator level. A. and B. Shown 
are schema of the experimental design in panels C. and D., respectively. C. Wildtype (WT) B. 
anthracis and ΔhssS/Δ1816 were transformed with the hrt promoter fused to the xylE reporter 
gene (phrt.xylE) and the hrt DR swapped into the BAS1814 promoter (p14.hrtDR.xylE). The four 
strains were each treated with either 50 µM ‘205 or an equivalent volume of the vehicle DMSO. 
Cultures were grown for 24 h and harvested. Cells were lysed and XylE activity was quantified. 
D. Wildtype (WT) B. anthracis and ΔhssR/Δ1817 were transformed with the 14 promoter fused 
to the xylE reporter gene (p14.xylE) and the 14 DR swapped into the hrt promoter 
(phrt.14DR.xylE). The four strains were each treated with either 1 µM heme or an equivalent 
volume of the vehicle 0.1 M NaOH. Cultures were grown for 24 h and harvested. Cells were 
lysed and XylE activity was quantified. In all instance, data are averaged from at least two 
independent experiments performed with biological triplicates. Error bars represent the standard 
error of the mean.   
95 
 
The analogous phosphotransfer from HssS to BAS1816 was tested by the same strategy. 
A Δ1817/ΔhssR double knock-out strain was generated and transformed with p14.xylE and 
phrt.14DR.xylE, which has the p14 DR inserted in phrt. If phosphotransfer from HssS to 
BAS1816 occurs in vivo, then the p14.xylE is predicted to be activated in Δ1817/ΔhssR in the 
presence of heme (Figure 25B). This does indeed occur, suggesting that in vivo HssS may cross-
phosphorylate BAS1816 to stimulate activation of p14 (Figure 25B and D). These data suggest 
that at low heme concentrations the signaling integrity of HssRS activation of phrt may be 
maintained by the higher phosphotransfer preference of HssS to HssR (Figure 24), the enhanced 
activity of HssR at phrt (Figure 21), and perhaps even phosphatase activity of BAS1817 on 
BAS1816. However, at higher heme concentrations the mechanism by which heme activates p14 
may occur either through cross-phosphorylation from HssS to BAS1816 (Figure 24) or activation 
of p14 by HssR (Figure 22B). It is intriguing that the ‘least preferred’ cross-phosphorylation from 
HssS to BAS1816 in vitro is observed in vivo, but the parallel cross-phosphorylation from 
BAS1817 to HssR is not. Perhaps there is a certain threshold of HK activation that must be 
achieved in order to observe cross-phosphorylation. It is possible that heme-induced activation of 
HssS exceeds this threshold, but ‘205-induced stimulation of BAS1817 does not. Perhaps with 
more potent BAS1817 activators cross-phosphorylation from BAS1817 to HssR may be 
observed.  
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The identification of BAS1816-17 activators. Since compound ‘205 is not likely to be an 
environmental signal typically encountered by B. anthracis, the native function of BAS1816-17 
was interrogated. Identifying the native function of BAS1816-17 would not only inform the 
potential function of the BAS1814-15 ABC transporter, but may also reveal why HssRS and 
BAS1816-17 interact. To identify other signals that activate BAS1816-17 a chemical biology 
approach was undertaken, this time employing the Biolog Phenotypic Microarray. 
 The first twenty 96 well plates (PM1-20) were purchased from Biolog’s Phenotypic 
Microarray Library for Microbial Cells. Each well contains a different compound that may 
differentially impact the growth and behavior of bacteria. The first ten plates interrogate different 
nutrient environments (e.g. carbon sources) and the second ten plates probe different chemical 
sensitivities (e.g. antibiotics). Wildtype B. anthracis transformed with p14.xylE was grown in 
each of these plates and activation of p14 was monitored by XylE assay. The screen was repeated 
twice and the twelve molecules that activated p14.xylE were repurchased from commercial 
vendors. The specific activation of BAS1816-17 was tested by exposing both wildtype and 
Δ1816-17 p14.xylE to each compound in a concentration range that spanned at least 2-logs and 
did not inhibit bacterial growth. Four compounds exhibit specific activation of p14.xylE in a 
manner that requires BAS1816-17.  
The most potent activator identified is nordihydroguaiaretic acid (NDGA), which is even 
more active than ‘205 (Figure 26A). NDGA is an antioxidant isolated from the creosote bush; the 
long life of the bush is attributed to the antimutagenic effects of NDGA (45). Several other 
activities have been ascribed to the molecule as well including anti-inflammatory and antiviral 
activities (45). 
The second best activator of BAS1816-17 identified in the phenotypic microarray is 
chlorpromazine (Figure 26B). Chlorpromazine is used to treat allergies and psychoses in humans, 
but it also sensitizes humans to light (15). This effect is thought to result from photoactivation of 
chlorpromazine and subsequent intercalation into DNA (54). Not surprisingly, chlorpromazine is 
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mutagenic in the Ames test (55). Chlorpromazine uncouples oxidative phosphorylation and has 
also been implicated in disrupting passive transport across mitochondrial membranes (65, 81). In 
bacteria, most work has been focused on the chemorepellent activity of chlorpromazine to 
Bacillus subtilis (56). Though one study notes that chlorpromazine inhibits cell wall biogenesis in 
Bacillus megaterium (38). 
Both low concentrations of vancomycin and high concentrations of sodium phosphate 
(pH 7) were found to weakly activate BAS1816-17 (Figure 26D and E). The concentration range 
of vancomycin is limited due to the antibiotic nature of the compound. Vancomycin is best 
known for inhibiting Gram positive cell biosynthesis, but at low concentrations it has also been 
shown to disrupt membrane integrity (95). The anion sodium phosphate only showed weak 
activity at high concentrations, beyond which significant growth defects were observed. 
The description of the biological activity of each of these compounds in the literature, 
leads to the hypothesis that BAS1816-17 may be activated by cell envelope stressors. Recently, a 
small molecule inhibitor of S. aureus wall techoic acid (WTA) synthesis called targocil was 
identified (89). Targocil inhibits the transport of the nascent WTA from inside the membrane to 
the outer surface. This not only results in a loss of cell wall integrity, but may also cause an 
accumulation of negative charges near the inner leaflet due to the accumulation of poly(ribitol-
phosphate) components of WTA inside the cell (89). The activity of targocil on the Gram positive 
cell envelope indicated that this small molecule may also activate BAS1816-17. To test this 
hypothesis the activation of p14.xylE in wildtype and Δ1816-17 B. anthracis in response to 
targocil was investigated. Targocil does specifically activate the BAS1814 promoter in a manner 
that requires BAS1816-17 (Figure 26C). A microarray performed on targocil treated S.aureus 
revealed the transcriptional up-regulation of hrtAB 12-fold (10). This was the second most up-
regulated operon next cwrA a small peptide of unknown function that is a reporter of cell wall 
stress (10). 
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Figure 26. Five novel activators of BAS1816-17. Wildtype (WT) B. anthracis and ΔBAS1816-
17 were transformed with the 14 promoter fused to the xylE reporter gene (p14.xylE). The strains 
were treated with either 50 µM ‘205 or a range of concentrations of the following compounds: A. 
nordihydroguaiaretic acid (NDGA), B. chlorpromazine, C. targocil, D. vancomycin, and E. 
sodium phosphate pH 7. Cultures were grown for 6 h and harvested. Cells were lysed and XylE 
activity was quantified. In all instances, data are averaged from at least two independent 
experiments performed with biological triplicates. Error bars represent the standard error of the 
mean. The primary Biolog screen was performed by PB. 
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In summary, five novel activators of BAS1816-17 have been identified, including one 
compound, NDGA, that is more potent than ‘205. The common mechanism by which these 
molecules activate BAS1816-17 remains to be determined. The current understanding of the 
mode of action of each of these compounds, points to the hypothesis that BAS1816-17 may be 
activated by alterations in the cell envelope, perhaps disruptions in the electrochemical potential 
across the membrane. To identify common cellular events that result in BAS1816-17 activation, 
RNASeq analysis of B. anthracis treated with vehicle, ‘205, NDGA, chlorpromazine and targocil 
will be employed. Theoretically, there should be shared transcriptional responses to each of the 
BAS1816-17 activators since they all stimulate this new TCS. Identifying common transcriptional 
changes upon treatment with these compounds will provide insight to the native cellular signal 
that activates BAS1816-17. 
 
Discussion 
 In this chapter a small molecule activator of S. aureus HssRS was used to identify a new 
TCS in B. anthracis. This TCS BAS1816-17 recognizes a DR in p14 that differs from the phrt 
DR by four nucleotides. These four nucleotides are the primary source of differential regulation 
between phrt and p14. It is not surprising then, in the absence of HssR, BAS1816-17 activates 
expression of both p14 and phrt. Through both in vitro and in vivo experiments BAS1816-17 has 
been determined to regulate phrt at the RR-DR level, while HssRS impacts expression at p14 
either through HK-RR or RR-DR interactions. The interactions between HssRS and BAS1816-17 
are summarized in Figure 27.  
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Figure 27. A summary of cross-talk observed between HssRS and BAS1816-17 in B. 
anthracis. A-C. HssRS was previously shown to be stimulated by heme to activate phrt (83). D-
F. Here a second TCS BAS1816-17 has been identified to be stimulated by ‘205 to activate p14. 
G. and H. At the RR-DR level BAS1816 can recognize the phrt DR but HssR only recognizes the 
p14 DR only in the context of phrt. I. and J. At the HK-RR level HssS can cross-phosphorylate 
BAS1816 both in vitro and in vivo, while BAS1817 has only been observed to cross-
phosphorylate HssR in vitro. 
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 In addition, five new activators of BAS1816-17 were identified and will be used to 
determine the native function of BAS1816-17 and the nature of BAS1816-17 cross-talk with 
HssRS. Here, the impact of each of these new activators on BAS1816-17 mediated stimulation of 
p14 was investigated. In order to more fully dissect the mechanisms of TCS cross-talk, the impact 
of each of these small molecules on phrt activation should be determined. Such studies may 
reveal how these compounds activate BAS1816-17 and further dissect the cross-talk between 
BAS1816-17 and HssRS. Without this panel of non-native small molecule activators of 
BAS1816-17, the studies presented here characterizing this new TCS and its mechanisms of 
cross-talk with HssRS would have been impossible. Delineating the activity and function of many 
TCSs is limited by a lack of known activators. The success of the Biolog Phenotypic MicroArray 
for identifying activators of BAS1816-17 is applicable to any TCS and may be a powerful new 
chemical biology based strategy that will improve the tools available for studying TCSs.  
 The known activities of the six BAS1816-17 activating compounds lead to the hypothesis 
that BAS1816-17 may be activated by perturbations in the cell envelope, potentially even 
alterations in the electrochemical gradient across the membrane. The lipophilic nature of the 
protoporphyrin IX ring, which coordinates iron, disrupts the cell membrane of erythrocytes (1). 
This causes hemolysis by a colloid-osmotic mechanism as the cells no longer maintain ion 
gradients and water enters the cell. In addition, S. aureus heme-iron preferentially accumulates in 
the cell membranes (77). It is possible that HssRS is activated when heme disrupts the membrane. 
This model is supported by the previous observation that targocil, which prevents translocation of 
WTA to the outer leaflet of the cell membrane, activates HssRS in S. aureus (10, 89). It is 
possible that general membrane stress activates BAS1816-17 and is alleviated by activation of 
p14. The function of the putative ABC transporter BAS1814-15 is unknown. Perhaps it transports 
an osmoprotectant which could more generally protect against any membrane stress, even heme. 
The coordinated expression of hrtAB and BAS1814-15 may enable B. anthracis to better cope 
with heme-induced membrane stress. 
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 Cross-regulation between HssRS and BAS1816-17 could exist if the activation of both 
phrt and p14 help alleviate heme toxicity. In Lactococcus lactis HrtAB has been shown to efflux 
heme (42). In wildtype B. anthracis p14 is activated in the presence of high concentrations of 
heme; meanwhile, activation of phrt in the presence of ‘205 has not been consistently observed. 
This suggests that some cross-regulation may exist from HssRS to BAS1816-17 and that 
BAS1814-15 may help alleviate heme toxicity. The lack of cross- talk from BAS1816-17 to 
HssRS upon ‘205 treatment suggests that HrtAB may not be needed upon BAS1816-17 activation 
or that ‘205 is not a strong enough activator of BAS1816-17 to achieve cross-talk. It would be 
worthwhile to investigate whether cross- talk from BAS1816-17 to HssRS occurs in the presence 
of the more potent activator NDGA.  
 In a more general sense, the interactions between HssRS and BAS1816-17 suggest that B. 
anthracis may be able to integrate multiple signals to better adapt and survive in diverse 
environments. BAS1814-17 is only conserved in the Bacillus genus, it is not found in other hssRS 
encoding bacteria outside this genus. Perhaps this is due to the unique coordination of a 
sporulation program which the Bacilli must integrate with signals from diverse niches including 
soil, water, plant surfaces, and various insect and mammalian hosts. Alternatively, the cross-
signaling between HssRS and BAS1816-17 may occur to supplement HssRS-mediated heme 
tolerance. B. anthracis HssRS is more active than S. aureus HssRS and ∆hrtA B. anthracis is 
more sensitive to heme toxicity than ∆hrtA S. aureus (83). These data suggest that B. anthracis 
has differential sensitivities and responses to heme toxicity and it is possible that BAS1814-17 
contributes to Bacilli adapting to heme stress. 
 BAS1816-17 and HssRS are more closely related to each other than any of the 45 other 
TCSs in B. anthracis. Moreover, the DR recognized by each RR differs by only four nucleotides. 
BAS1816-17 is only found in the Bacillus genus. These observations suggest that perhaps 
BAS1816-17 is a paralogous HssRS system in the Bacillus genus and that the two TCSs have not 
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diverged enough to completely eliminate cross-talk. The question remains whether the cross-talk 
between the TCSs is beneficial to the bacteria and therefore selectively maintained. 
 One of the most interesting results observed here is the re-engineering of p14 to be 
strongly responsive to heme exposure. Upon deletion of HssR and BAS1817, the stimulation of 
HssS with heme presumably results in the phosphotransfer from HssS to BAS1816 and 
subsequent activation of p14. These results rejoin an idea proposed by Laub and Goulian who 
stated that: 
“...the ultimate test of whether we understand the specificity of 
protein-protein interactions throughout two-component pathways 
will be whether we can redesign or rationally engineer these 
systems. Can pathways, in effect, be rewired to execute novel 
functions (41)?” 
 
In this chapter, the dissection of cross-talk between HssRS and BAS1816-17 has in fact allowed 
us to rewire the B. anthracis response to heme toxicity. This provides an exciting foundation for 
controlling B. anthracis signaling networks and potentially manipulating the bacterial response to 
its environment.  
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CHAPTER VI 
 
SUMMARY 
 
Conclusions 
 S. aureus and B. anthracis are two closely related pathogens. The pathogenesis of each of 
these organisms often consists of a significant blood component. While the blood is relatively 
devoid of free iron, both S. aureus and B. anthracis are capable of lysing red blood cells and 
acquiring heme-coordinated iron from host hemoglobin (50, 51, 58). This heme can be degraded 
to release free iron or trafficked to the cell membrane, presumably for use intact as a protein co-
factor (75-77). An overabundance of heme is toxic, but these pathogens can alleviate heme 
toxicity by activating the heme regulated transporter (HrtAB) through the heme sensing system 
(HssRS) (85, 90). The hssRS/hrtAB systems are conserved across Gram positive pathogens as a 
mechanism for overcoming the heme paradox (1, 90). Identifying the mechanisms by which 
HssRS senses heme toxicity will provide insight into the mechanisms by which many Gram 
positive pathogens successfully adapt to the mammalian host. 
 Here a chemical genetics approach was utilized for dissecting the mechanisms of HssRS 
activation. An HTS for small molecule activators of S. aureus HssRS resulted in the identification 
of approximately fifteen small molecules that activate HssRS. These top compounds were then 
screened for activity in B. anthracis and several were also able to stimulate the hrt promoter 
(phrt) in B. anthracis. This chemical genetics approach to probing TCS biology has yielded new 
models for how bacteria regulate heme homeostasis, innovative strategies for targeting bacterial 
energy production during infection, and a deeper understanding of how bacterial signaling 
networks are integrated to enable adaptation to complex environments. 
 Identified in the VICB small molecule library, compound ‘882, was the most potent 
activator of S. aureus HssRS. To dissect the mechanism of ‘882-induced HssRS activation, the 
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residues required for heme sensing by HssS were compared to the residues required for ‘882 
sensing and found to be similar. This suggested a common mechanism of HssS activation by both 
‘882 and heme. The simplest hypothesis is that ‘882 stimulates endogenous heme biosynthesis to 
activate HssS. This is indeed the case as HssS is not activated by ‘882 in a strain lacking 
endogenous heme biosynthesis and ‘882 treatment results in the accumulation of intracellular 
heme. Since ‘882 stimulates endogenous heme this indicates that HssS actually senses 
intracellular heme stress. These studies neither rule out the possibility that HssS may directly 
sense heme, nor that a product of heme toxicity is the ligand of HssS.  
 The stimulation of endogenous heme biosynthesis by ‘882 is unprecedented and provides 
an excellent probe for studying the regulation of endogenous heme biosynthesis. To study how S. 
aureus regulates heme biosynthesis, genes that contribute to ‘882 sensing were identified in a 
transposon screen. Many genes involved in central metabolism contributed to the activation of 
HssRS by ‘882. In fact, when multiple metabolic parameters of S. aureus energy production were 
monitored, it was determined that ‘882 suppresses fermentation. This suggests that heme 
biosynthesis may, in part, be regulated by the metabolic state of the cell. This is intuitive as heme 
is a critical co-factor for enzymes involved in energy homeostasis, most notably the cytochromes 
in the electron transport chain.  
 The hypothesis that heme biosynthesis is integrated with energy homeostasis is bolstered 
by the observation that suppressing upper glycolysis coordinately suppressed heme biosynthesis. 
While it is clear that the energetic state of the bacterial cell impacts the regulation of heme 
biosynthesis, the exact cellular signals and factors that form the interface between these two 
cellular processes remain elusive. Further studies utilizing ‘882 and knowledge gained here may 
help tease apart these fundamental aspects of S. aureus physiology. 
 The noted impact of ‘882 treatment on fermentative processes evoked the intriguing 
possibility that ‘882 may adversely affect S. aureus under conditions where the bacteria are 
generating energy solely by fermentation. This proved to be correct as growth of S. aureus in an 
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anaerobic chamber dramatically lowers the IC50 of ‘882 for wildtype S. aureus. The IC50 is further 
reduced for the two lab generated SCV strains hemB::ermC and ∆menB, which rely on 
fermentation to generate energy. These data, along with other data presented in Chapter III, 
indicate that ‘882 is specifically toxic to fermenting S. aureus.  
 No known antibiotics specifically target energy production in bacteria, especially 
fermentation, despite it being thought to be an important component of infection. Furthermore, 
identifying fermentation inhibitors by HTS is difficult to perform due to the required outfitting of 
an anaerobic chamber with HTS equipment. Thus, compound ‘882 presents a unique tool for 
investigating the importance of fermentation in bacterial pathogenesis and antibiotic resistance.  
 In dual therapy, ‘882 prevents the outgrowth of antibiotic resistance to gentamicin, 
reaffirming that fermentation is required for resistance to aminoglycosides. Furthermore, 
gentamicin is not used in monotherapy to treat S. aureus infections due to the high association of 
antibiotic resistance; it is sometimes used in a combination with a β-lactam or vancomycin, which 
is synergistic. The prevention of resistance to gentamicin by ‘882 has exciting potential to expand 
the current strategies used to treat S. aureus infections by repurposing an already approved 
antibiotic. This strategy is analogous to the antibiotic coctail amoxicillin-clavulanate, which 
combines a β-lactam with a β-lactamase inhibitor. This combination therapy prevents bacterial β-
lactamases from inactivating amoxicillin and successfully treats many bacterial infections. 
 In monotherapy, ‘882 enhances neutrophil mediated killing of S. aureus ex vivo, and in 
vivo the ‘882 derivative, ‘373, reduces bacterial and abscess burdens in the liver. These exciting 
observations indicate that fermentation is important in vivo. That is, at certain points during 
pathogenesis S. aureus must rely on fermentation to successfully colonize the host. These 
processes most likely include resisting phagocytosis and forming absecesses. Since fermentation 
is a branched process, and since ‘882 seems to target fermentation in general, these data provide 
an insight into the role of fermentation in pathogenesis which cannot be provided with traditional 
genetic techniques.  
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 Fermentation is likely to be important in pathogenesis more generally. Many pathogens 
including the Clostridia and the Streptococci genera only ferment, but most pathogens are more 
akin to S. aureus in that they are metabolically flexible and can generate energy through both 
fermentation and respiration. Since many pathogens utilize fermentation, it is possible that 
targeting this important energy generating process may be a new antibiotic strategy. This is 
supported by the observation that ‘882 is also toxic to C. diphtheriae in vitro. Further work 
investigating the anaerobic toxicity of ‘882 toward other pathogens or screening for other small 
molecules that target fermenting bacteria may provide valuable tools to the medical community 
for broadening the therapeutic strategies used to combat recalcitrant pathogens. As highlighted at 
the beginning of this section, compounds that manipulate energy homeostasis may also be 
powerful probes for understanding basic bacterial physiology. 
 The sensitivity of S. aureus to ‘882 under anaerobic conditions indicates that there are 
processes absolutely critical to anaerobic growth. Identifying the source of ‘882 toxicity would 
allow future studies to develop small molecules with better activity either through SAR 
improvements of ‘882 or the identification of other inhibitors by HTS. In order to identify the 
source of ‘882 toxicity, spontaneously ‘882-resistant strains were isolated and determined to have 
genetic mutations that result in lost SaeRS activity. Studying the ‘882 sensitivity profiles of a 
series of isogenic sae operon mutants revealed that it is the hyperactivity of S. aureus strain 
Newman SaeS that results in anaerobic ‘882 toxicity.  
 Although it is possible that a detrimental cross-talk event between the SaeRS and HssRS 
TCSs could be the source of toxicity, our current hypothesis is that a cellular factor impacted by 
SaeRS function is the source of ‘882 toxicity.  The current model is that ‘882 interacts with a 
protein up-regulated by SaeRS activity to generate a toxic by-product that cannot be tolerated in 
anaerobic conditions. Ablating SaeRS activity could titrate that target to low levels which may 
prevent ‘882 toxicity from occurring. Identifying the source of anaerobic ‘882 toxicity will 
provide insight into S. aureus physiology and point to potential antibacterial drug targets. 
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 Work presented here highlights the utility of ‘882 as a probe of S. aureus cell biology and 
identifies new therapeutic strategies for treating S. aureus infections. At the most basic level, ‘882 
has revealed that bacterial heme sensors may generally sense intracellular heme, not only 
extracellular heme as previously thought. To determine if any of the hits from the HTS may also 
prove to be powerful probes of HssRS activity and provide additional insights into basic bacterial 
biology in other species, the top hits from the HTS were screened for phrt activation in B. 
anthracis.  
 Compound ‘205 was identified to activate phrt independent of HssRS. This is due to the 
activation of a previously uncharacterized TCS BAS1816-17. BAS1816-17 was predicted to 
regulate a DR in p14, which is similar to the phrt DR recognized by HssR (12). Using ‘205 to 
stimulate BAS1816-17 enabled the dissection of a complex signaling network between 
BAS1816-17 and HssRS. The four nucleotides that differentiate the phrt and p14 DRs are 
sufficient to determine the response of each promoter to heme or ‘205. The exception is that the 
high basal activity of the phrt promoter requires the phrt DR, but the phrt DR is not sufficient to 
induce high basal activation of the p14 promoter. In all, the high basal activity of phrt requires the 
phrt DR, HssR, and the approximately 200 bp that encompass phrt. This implicates other cis- or 
trans-acting cellular factors in the high basal level of phrt activation. Despite the high basal 
activity of phrt, it is clear that BAS1816-17 can interact with phrt at the RR-DR level. 
Correspondingly, p14 is activated in high concentrations of heme and this may occur at either the 
HK-RR or RR-DR level.  
 The activation of p14 by heme-stimulated HssRS in wildtype S. aureus indicates that 
there is natural cross-talk between these systems. The function of BAS1814-15 and why it is 
activated in the presence of heme remains unclear. To better understand the function of 
BAS1814-15 and the natural conditions that activate BAS1816-17, Biolog Phenotypic Microarray 
plates were used to identify four other activators of BAS1816-17. Although none of these 
activators have a known function in B. anthracis, studies on the activity of the compounds in 
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other organisms suggest that BAS1816-17 may be activated by cell envelope stress or alterations 
in the electrochemical potential across the cell membrane. This hypothesis is further supported by 
the identification of a sixth BAS1816-17 activator, targocil. Targocil inhibits the transport of 
WTAs to the outer leaflet of the S. aureus cell membrane, resulting in cell envelope stress and the 
accumulation of WTA on the inner leaflet of the membrane (89). Since WTA is polyanionic, 
targocil may not only disrupt the cell envelope but may also disrupt the electrochemical potential 
across the membrane. Confirming the natural function of BAS1816-17 is essential for 
understanding if the cross-talk between HssRS and BAS1816-17 is a relic of evolutionary 
similarity between the TCSs or a beneficial event that enables Bacilli to adapt to multiple 
environmental perturbations. If cross-regulation between HssRS and BAS1816-17 is indeed 
advantageous, identifying the ligand of each HK and the substrate of each ABC transporter 
(HrtAB and BAS1814-15) may clarify the mechanisms of heme toxicity and tolerance in Gram 
positive pathogens. 
 
Future directions 
Elaborate the mechanisms by which heme homeostasis and energy metabolism are 
coordinated. Studies presented here point to the coordination of S. aureus heme biosynthesis 
with energy homeostasis. Inhibiting upper glycolysis suppresses heme biosynthesis while 
repressing fermentation stimulates heme biosynthesis. These observations suggest that a 
metabolic signal produced between upper glycolysis and fermentation regulates heme 
biosynthesis. The model is that inhibiting upper glycolysis decreases the metabolic signal and 
coordinately reduces heme biosynthesis, while inhibiting fermentation results in a build-up in the 
metabolic signal, which stimulates heme biosynthesis.  
 In order to identify the metabolic signal that regulates heme biosynthesis, a combined 
genetic and chemical biology approach may continue to provide insights. Each step in glycolysis 
and fermentation may be systematically inhibited either by genetically ablating each gene or 
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chemical targeting each step. The effect of manipulating each step in glycolysis and fermentation 
on heme biosynthesis may reveal the source of the metabolic signal. 
 Alternatively, a primarily chemistry driven strategy may be employed to delineate the 
mechanisms by which central metabolism impacts heme biosynthesis. SAR studies on ‘882 have 
identified chemical moieties on ‘882 that tolerate permutation. At these points, compound ‘882 
may be modified to include probe-based elements. These elements can then be used to cross-link 
‘882 to cellular binding partners, which may then be identified by mass spectrometry. Identifying 
the true binding partners of ‘882 may help elucidate the mechanisms by which ‘882 is exerting its 
effects on both heme biosynthesis and anaerobic toxicity.  
 
Identify the source of ‘882 toxicity. The importance of identifying the source of anaerobic ‘882 
toxicity hinges on extending the utility of ‘882 from a probe of basic bacterial physiology to one 
that provides direction for the development of antibacterial agents. Presumably ‘882 is 
manipulating S. aureus metabolism in a way that is incompatible with fermentative growth. 
Understanding what S. aureus cannot tolerate under anaerobic conditions will aid in improving 
‘882 activity or identifying more effective molecules that target bacterial energy production. 
 Current efforts to identify the source of anaerobic ‘882 toxicity are focused on 
determining the role of SaeRS regulated gene targets in providing resistance to ‘882 or sensitivity 
to anaerobic growth. Approximately 80% of the genes predicted to be regulated by SaeRS under 
anaerobiosis are available in the NARSA S. aureus defined transposon library. Since the other 
20% are not identified in the NARSA library, this suggests that they may be essential. The genes 
available in the NARSA library will be transduced into S. aureus strain Newman and then 
assessed for ‘882 sensitivity. If none of those genes prove to be the source of anaerobic toxicity, 
this will narrow the list of potential targets to the other 20% of the SaeRS regulatory targets. 
Either chemical inhibitors or siRNAs may be used to titrate levels of the remaining putative 
targets and subsequently investigate their role in anaerobic growth and ‘882 toxicity. 
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Correspondingly, each remaining gene of interest could be cloned under a constitutive promoter 
to assess the effect of overexpression of these putative targets on ‘882 toxicity and anaerobic 
growth. 
 Since ‘882 suppressor strains arose at a mutation rate of 1 in 107 bacteria and all have 
non-functional SaeRS TCSs, this indicates that mutation of the sae operon happens at a rate 
similar to most other genes in the genome. Viable mutations in the true target of ‘882 may occur 
at a much lower frequency if they affect bacterial fitness. In order to try to identify other genetic 
loci involved in ‘882 resistance, the saePQRS operon will be integrated into the hlb locus of S. 
aureus strain Newman (5). This will yield a merediploid strain of S. aureus carrying two copies 
of the sae locus. ‘882 suppressor colonies could then be isolated in this strain. Since there will be 
two copies of sae, the likelihood of isolating a strain with mutations at both sae loci will be lower 
and may permit the identification of other loci involved in providing resistance to ‘882. The 
mutations can be identified by whole genome sequencing. The role each mutation plays in 
anaerobic growth and ‘882 toxicity could then be further assessed to determine if it affects the 
cellular target of ‘882 and may serve as a suitable therapeutic target. 
 
Define the native function of BAS1814-17. BAS1814 and BAS1815 comprise the predicted 
ABC transporter regulated by the TCS BAS1816-17. The p14 promoter is activated in the 
presence of ‘205 by BAS1816-17 and high heme concentrations by HssRS. The impact this cross-
talk has on B. anthracis heme toxicity and tolerance remains to be explored. Identifying the 
native function of BAS1814-17 may reveal whether there is a biological benefit of 
HssRS/BAS1816-17 cross-talk 
 Currently, six BAS1816-17 activators have been identified. Their known activity in other 
systems suggests that BAS1816-17 may be sensing perturbations in the cell envelope, perhaps 
changes in the electrochemical gradient. To identify common cellular events that trigger 
BAS1816-17 activation, RNASeq could be employed. An RNASeq analysis comparing genes 
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altered in B. anthracis upon exposure to each BAS1816-17 activator may reveal transcriptional 
changes induced by multiple compounds. Identifying common transcriptional changes that 
precede BAS1816-17 activation may either confirm that cell envelope stress is indeed a likely 
activator of BAS1816-17 or may generate other hypotheses about the native function of 
BAS1816-17. If the activation of BAS1814-17 by heme does have a biological purpose then 
understanding the native function of this new TCS and ABC transporter will provide insights into 
the mechanisms by which Gram positive bacteria overcome the heme paradox during infection. 
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